**Exhibit      10.4**

**LICENSE      AGREEMENT**

**BETWEEN**

**INEX      PHARMACEUTICALS CORPORATION**

**AND**

**HANA      BIOSCIENCES, INC.**

----

**LICENSE      AGREEMENT**

**TABLE      OF CONTENTS**

| **Article                1 INTERPRETATION**                           | **1**                                                          |
|-----------------------------------------------------------------------|----------------------------------------------------------------|
| 1.1                                                                   | Definitions                                                    | 1 |
| 1.2                                                                   | Other                Definitions                               | 13 |
|                                                                  |                                                           |   |
| **Article                2 LICENSED PATENT AND LICENSED TECHNOLOGY**  | **13**                                                         |
| 2.1                                                                   | License                                                        | 13 |
| 2.2                                                                   | License                Grant to INEX                           | 14 |
| 2.3                                                                   | Compliance                with Third Party Agreements          | 14 |
| 2.4                                                                   | Sublicensing                                                   | 14 |
| 2.5                                                                   | Payment                of Taxes                                | 16 |
|                                                                  |                                                           |   |
| **Article                3 LICENSE FEES, MILESTONES AND ROYALTIES**   | **1****6**                                                     |
| 3.1                                                                   | Sphingosomal                Vincristine                        | 16 |
| 3.2                                                                   | Sphingosomal                Vinorelbine                        | 18 |
| 3.3                                                                   | Sphingosomal                Topotecan                          | 20 |
| 3.4                                                                   | Limitation                on Payment Using Common Stock        | 22 |
| 3.5                                                                   | Assumption                of Milestone and Royalty Obligations | 22 |
| 3.6                                                                   | Remuneration                Respecting Sublicensees            | 23 |
| 3.7                                                                   | Third                Party Payments                            | 25 |
| 3.8                                                                   | Compulsory                Licenses                             | 26 |
| 3.9                                                                   | Reports                and Payment                             | 27 |
| 3.10                                                                  | Withholding                Taxes                               | 27 |
| 3.11                                                                  | Foreign                Payments                                | 28 |
| 3.12                                                                  | Method                of Payment                               | 28 |
| 3.13                                                                  | Late                Payments                                   | 28 |
| 3.14                                                                  | Records                                                        | 28 |
| 3.15                                                                  | Audits                                                         | 28 |
|                                                                  |                                                           |   |
| **Article                4 DEVELOPMENT OBLIGATIONS**                  | **29**                                                         |
| 4.1                                                                   | Development                Plans                               | 29 |
| 4.2                                                                   | Development                Efforts                             | 29 |
| 4.3                                                                   | Transition                Committees                           | 29 |
| 4.4                                                                   | Subcontractors                                                 | 29 |
|                                                                  |                                                           |   |
| **Article                5 COMMERCIALIZATION OBLIGATIONS**            | **30**                                                         |
| 5.1                                                                   | Regulatory                Compliance                           | 30 |
| 5.2                                                                   | Marqibo                Trademark                               | 30 |
| 5.3                                                                   | Labeling                and Patent Marking                     | 30 |
| 5.4                                                                   | Commercialization                Efforts                       | 30 |
| 5.5                                                                   | Consequence                of No Sales                         | 30 |
| 5.6                                                                   | Reports                                                        | 31 |
|                                                                  |                                                           |   |
| **Article                6 PRODUCT SAFETY AND REGULATORY COMPLIANCE** | **31**                                                         |
| 6.1                                                                   | Regulatory                Responsibilities                     | 31 |
| 6.2                                                                   | Pharmacovigilance                                              | 32 |
| 6.3                                                                   | Recalls                and Product Withdrawals                 | 33 |
|                                                                  |                                                           |   |
|                                                                  |                                                           |

----

| **Article                7 INTELLECTUAL PROPERTY RIGHTS**               | **33**                                                                  |
|-------------------------------------------------------------------------|-------------------------------------------------------------------------|
| 7.1                                                                     | Injunctive                Relief                                        | 33 |
| 7.2                                                                     | INEX                Title                                               | 34 |
| 7.3                                                                     | Ownership                of Pre-existing Intellectual Property Rights   | 34 |
| 7.4                                                                     | Ownership                of Future Intellectual Property Rights         | 34 |
|                                                                    |                                                                    |   |
|                                                                    |                                                                    |
| **Article                8 PATENT PROSECUTION AND MAINTENANCE**         | **35**                                                                  |
| 8.1                                                                     | IP                Committee                                             | 35 |
| 8.2                                                                     | Responsibility                for Patent Prosecution and Maintenance    | 35 |
| 8.3                                                                     | Consultation                and Reporting                               | 37 |
| 8.4                                                                     | Reports                                                                 | 37 |
| 8.5                                                                     | Abandonment,                Withdrawal or Discontinuance                | 37 |
| 8.6                                                                     | Costs                of Patent Application, Prosecution and Maintenance | 39 |
| 8.7                                                                     | Late                Payments                                            | 40 |
| 8.8                                                                     | Co-operation                                                            | 41 |
|                                                                    |                                                                    |   |
| **Article                9 INFRINGEMENT PROCEEDINGS**                   | **41**                                                                  |
| 9.1                                                                     | Limits                                                                  | 41 |
| 9.2                                                                     | Conduct                of Infringement Proceedings                      | 41 |
| 9.3                                                                     | Breach                of Confidence Proceedings                         | 42 |
| 9.4                                                                     | Defense                of Infringement Proceedings                      | 43 |
| 9.5                                                                     | Co-operation                with Other Licensees                        | 44 |
|                                                                    |                                                                    |   |
| **Article                10 CONFIDENTIAL INFORMATION AND PUBLICATION**  | **44**                                                                  |
| 10.1                                                                    | Treatment                of Confidential Information                    | 44 |
| 10.2                                                                    | Permitted                Disclosures                                    | 45 |
| 10.3                                                                    | Liability                for Representatives                            | 46 |
| 10.4                                                                    | Publications                Generally                                   | 46 |
| 10.5                                                                    | No                Limitation on Regulatory Compliance                   | 46 |
| 10.6                                                                    | Return                of Confidential Information                       | 46 |
|                                                                    |                                                                    |   |
| **Article                11 REPRESENTATIONS AND WARRANTIES**            | **47**                                                                  |
| 11.1                                                                    | Hana                Representations and Warranties                      | 47 |
| 11.2                                                                    | INEX                Representations and Warranties                      | 48 |
| 11.3                                                                    | DISCLAIMER                                                              | 49 |
|                                                                    |                                                                    |   |
| **Article                12 INDEMNIFICATION AND LIABILITY LIMITATIONS** | **49**                                                                  |
| 12.1                                                                    | Indemnification                by Hana                                  | 49 |
| 12.2                                                                    | Indemnification                by INEX                                  | 50 |
| 12.3                                                                    | Notice                of Claims                                         | 50 |
| 12.4                                                                    | Consequential                Losses                                     | 51 |
| 12.5                                                                    | Actions                Between the Parties                              | 51 |
| 12.6                                                                    | Insurance                                                               | 51 |
|                                                                    |                                                                    |   |
| **Article                13 DISPUTE RESOLUTION**                        | **52**                                                                  |
| 13.1                                                                    | Negotiation                and Arbitration                              | 52 |
|                                                                    |                                                                    |   |

----

| **Article                14 TERM & TERMINATION** | **53**                                                    |
|------------------------------------------------------|-----------------------------------------------------------|
| 14.1                                                 | Term                                                      | 53 |
| 14.2                                                 | Termination                for Invalidity Challenge       | 54 |
| 14.3                                                 | Termination                on Bankruptcy                  | 54 |
| 14.4                                                 | Termination                for Material Breach            | 56 |
| 14.5                                                 | No                Limitation on Remedies                  | 57 |
| 14.6                                                 | Consequences                of Termination                | 57 |
| 14.7                                                 | Disposition                of Product                     | 57 |
| 14.8                                                 | Delivery                of Data and Materials and License | 57 |
|                                                 |                                                      |   |
| **Article                15 GENERAL PROVISIONS**     | **58**                                                    |
| 15.1                                                 | Amendments                                                | 58 |
| 15.2                                                 | Assignment                                                | 58 |
| 15.3                                                 | Counterparts;                Facsimile                    | 59 |
| 15.4                                                 | Entire                Agreement                           | 59 |
| 15.5                                                 | Enurement                                                 | 59 |
| 15.6                                                 | Exhibits                                                  | 59 |
| 15.7                                                 | Force                Majeure                              | 59 |
| 15.8                                                 | Further                Assurances                         | 59 |
| 15.9                                                 | Governing                Law                              | 59 |
| 15.10                                                | Headings                                                  | 59 |
| 15.11                                                | Independent                Legal Advice                   | 60 |
| 15.12                                                | International                Sale of Goods Act            | 60 |
| 15.13                                                | Jurisdiction                                              | 60 |
| 15.14                                                | Non-Use                of Names                           | 60 |
| 15.15                                                | Notices                                                   | 60 |
| 15.16                                                | No                Implied Rights                          | 61 |
| 15.17                                                | No                Solicitation or Hiring of Employees     | 61 |
| 15.18                                                | No                Third-Party Rights                      | 61 |
| 15.19                                                | No                Waiver                                  | 61 |
| 15.20                                                | Publicity                                                 | 61 |
| 15.21                                                | Relationship                of Parties                    | 61 |
| 15.22                                                | Rights                and Remedies                        | 62 |
| 15.23                                                | Severability                                              | 62 |
| 15.24                                                | Survival                                                  | 62 |
| 15.25                                                | Wording                                                   | 62 |

----

**LICENSE      AGREEMENT**

**INEX      PHARMACEUTICALS CORPORATION**

**INEX**

**HANA      BIOSCIENCES, INC.**

**Hana**

| A.   | Pursuant                to an Transaction Agreement between INEX and Hana dated May 6, 2006                (the                “**Transaction                Agreement**”),                INEX has agreed to license to Hana certain Licensed Patents (as                hereinafter defined) and INEX Technology (as hereinafter defined)                relating                to the use of sphingosomes in the Hana Field (as hereinafter                defined); |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| B.   | Hana                and INEX acknowledge that the Licensed Patents and INEX Technology                provide                substantial value and significant barriers of entry in the Hana Field                for                any potential third-party competitor;                and |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| C.   | INEX                and Hana desire to set out in this Agreement the terms and conditions                which will govern the Parties’ respective rights and obligations in                respect of the Licensed Patents and INEX                Technology. |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      1**
**INTERPRETATION**

| **1.1  ** | **Definitions** |
|---------------------|-----------------|

| 1.1.1   | “**Abandoning                Party**”                shall have the meaning set forth in Section                8.5.1. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.2   | “**Adverse                Drug Event**”                means any noxious, unintended, or untoward medical occurrence in                a patient                or clinical investigation subject associated with the use of a medicinal                or investigational product, whether or not related to the medicinal                or                investigational product. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.1.3   | “**Affiliate**”                means, with respect to any Person, any Person directly or indirectly                controlled by, controlling or under common control with such Person.                For                the purposes of this definition, “control” shall mean direct or indirect                beneficial ownership of 50% or greater interest in the voting power                of                such Person or such other relationship as, in fact constitutes actual                control. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.4   | “**Agreement**”                means this License Agreement and all exhibits attached                hereto. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------|

| 1.1.5**  ** | **“Assesed                Value”**                shall have the meaning set forth in Section                3.6.6(b). |
|-----------------------|------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.6   | “**Applicable                Laws**”                means all applicable federal, provincial, state and local laws,                ordinances, rules and regulations of any kind whatsoever in the Territory,                including, without limitation, pharmaceutical and environmental rules                and                regulations, including cGMP Requirements, GCP Requirements, GLP                Requirements and the General Biological Products Standards of the                FDA, and                the Federal Food, Drug and Cosmetic Act, as amended, or any successor                act                thereto (“**FDCA**”). |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.7   | **“Bankruptcy                Action”**                shall have the meaning set forth in Section                14.3.3. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.8   | “**BCCA**”                means the British Columbia Cancer                Agency. |
|-------------------|------------------------------------------------------------------------------------------------|

| 1.1.9   | “**BCCA                Agreements**”                means the Research Project Agreement between INEX (formerly Lipex                Pharmaceuticals, Inc.) and the British Columbia Cancer Agency dated                February 25, 1993, and terminated May 6,                2002. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.10   | “**BCCA                Patents**”                means the egg sphingomyelin patents assigned by the British Columbia                Cancer Agency to INEX, that are subject to the rights of the British                Columbia Cancer Agency (including royalty rights) under the terms                and                conditions of the BCCA Agreements. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.11   | “**Business                Day**”                means any day other than a day which is a Saturday, a Sunday or a                statutory holiday in British Columbia                or                California. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.12   | “**Calendar                Quarter**”                means each of the three-month periods ending on March 31, June 30,                September 30 or December 31. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.13   | "**cGMP                Requirements**"                means the current Good Manufacturing Practices standards required                by the                FDA (as set forth in the FDCA), the Therapeutic Products Directorate                Organization of Health Canada ("**TPD**"),                and the European Medicines Evaluation Agency ("**EMEA**")                and any other jurisdiction as mutually agreed between the Parties                together                with their applicable regulations, policies or guidelines which are                in                effect for the manufacture and testing of pharmaceutical materials,                active                ingredients, or excipients for use in Phase I, Phase II, and Phase                III                clinical trials, as applicable. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.14   | “**Clinical                Activity**”                and “**Clinical                Activities**”                mean any one or more of the activities associated with drug testing                in                humans, including trial design and execution, payment of investigators’,                institutional, and contractors’ fees, drug distribution and                accountability, analytical testing, data management, statistical                analysis,                adverse event reporting, and scientific publication, performed in                pursuit                of the Development and Commercialization of a                Product. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.1.15   | “**Clinical                Trial Material**”                means labeled and packaged Sphingosomal Vincristine, Sphingosomal                Vinorelbine and/or Sphingosomal Topotecan, and any component(s) thereof,                used or to be used, in clinical                trials. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.16   | “**Closing                Payment**”                means an aggregate of One Million Five Hundred Thousand Dollars                ($1,500,000) in funds held in escrow                to                be paid by Hana to INEX pursuant to the terms and conditions of the                Transaction Agreement. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.17   | “**Closing                Shares**”                means the number of shares of Common Stock determined by dividing                Ten                Million Dollars ($10,000,000) by the FMV of the Common Stock as of                March                16, 2006                to be paid by Hana to INEX pursuant to the terms and conditions of                the                Transaction Agreement. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.18   | “**Commercialize**”                and “**Commercialization**”                mean the activities customarily associated with sales of pharmaceutical                products including without limitation, DDMAC Activities, price and                reimbursement negotiations, pre-launch and launch activities, marketing,                sales, distribution, post-approval Clinical Activities, the development,                prosecution, registration and maintenance of trademarks, trade names                and                domain names, and Pharmacovigilance in each country in the                Territory. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.19   | “**Commercially                Reasonable Efforts**”                means those efforts and resources that Hana would use were it developing,                promoting and detailing its own pharmaceutical products which are                of                similar market potential as the Products, taking into account product                labeling, market potential, past performance, economic return, the                regulatory environment and competitive market conditions in the                therapeutic area, all as measured by the facts and circumstances                at the                time such efforts are due. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.20   | “**Common                Stock**”                means the common stock of Hana, par value $0.001 per                share. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.21   | “**Confidential                Information**”                means all information, knowledge or                data: |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------|

| (a)   | of                an intellectual, technical, scientific or industrial nature, patentable                or                otherwise, in which a Party has a proprietary or ownership interest,                including, without limitation, technical data, drawings, photographs,                scans, specifications, standards, analytical methods, techniques,                manuals,                reports, formulas, compilations, processes, information, lists, trade                secrets, computer software, programs, devices, equipment, concepts,                inventions, designs, and know-how (including the INEX                Technology); |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | pertaining                to the business and affairs of a Party, including, without limitation,                financial information, marketing, manufacturing and commercial strategies,                patent positioning, business plans, strategies and developments,                including                any negative developments; or |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | provided                or disclosed to a Party by Third Parties subject to restrictions                on use or                disclosure, whether oral or written, furnished by the disclosing                Party to                the receiving Party or any of its Representatives, whether furnished                or                prepared before or after the Effective Date of this Agreement, and                includes all analyses, compilations, data, studies, reports or other                documents based upon or including any of such information, data or                knowledge and, in all cases, all copies and tangible embodiments                thereof,                in whatever form or medium; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (a)   | can                be demonstrated by the receiving Party by written record to have                been                known or otherwise available to the receiving Party prior to the                disclosure by the disclosing Party; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | can                be demonstrated by the receiving Party by written record to have                been in                the public domain at the time of                disclosure; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | after                disclosure, can be demonstrated by the receiving Party by written                record                to have subsequently become part of the public domain other than                as a                consequence of a breach of this Confidential Disclosure Agreement                by the                receiving Party or its                Representatives; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | after                disclosure, can be demonstrated by the receiving Party by written                record                to have been subsequently provided to the receiving Party by a Third                Party,                but only to the extent that the                receiving Party can                demonstrate that                such disclosure does not violate any obligations of the Third Party                to the                disclosing Party; or |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | the                receiving Party can demonstrate by                written records                results from research and development                activity conducted                by                the receiving Party or any of its Affiliates independently and in                advance                of disclosure by the other Party                thereof. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.22   | “**Damages**”                means any losses, liabilities, obligations, damages, penalties, fines,                claims, demands, actions, suits, costs and expenses of any nature                whatsoever, excluding indirect, special or consequential damages,                but                including, without limitation, legal fees, charges and disbursements,                and                the indirect, special or consequential damages of Third Parties for                which                a Party, INEX Indemnitees or Hana Indemnitees, as the case may be,                is                responsible. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.23   | “**DDMAC                Activities**”                mean all activities performed in accordance with the requirements                of the                Division of Drug Marketing, Advertising and Communications, Center                for                Drug Evaluation and Research of the FDA, and the Office of the Inspector                General of the Department of Health and Human Services of the United                States. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.24   | “**Definitive                Agreements**”                mean the Asset Purchase Agreement, Elan Assignment and Novation Agreement,                License Agreement, Service Agreement, UBC Sublicense Agreement;                Transaction                Agreement, and Registration Rights                Agreement. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.1.25   | “**Designated                EU States**”                means any one of Germany, the United Kingdom, Italy, France or                Spain. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.26   | “**Develop**”                and “**Development**”                means: |
|--------------------|--------------------------------------------------------------------------------------------------|

| (a)   | all                activities set forth in the Development Plan;                and |
|-----------------|-------------------------------------------------------------------------------------|

| (b)   | all                activities necessary to obtain and maintain Regulatory Approvals                in each                country in the Territory, including Clinical                Activities, Regulatory Activities,                Technical Transfer and Manufacturing                activities; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.27   | “**Development                Plan**”                means the development                plan for seeking                Regulatory Approvals for each Product in the Territory                during the initial twelve (12) months following the Effective                Date,                together with a corresponding budget accounting for the anticipated costs                to be expended or incurred by Hana in conducting the Development.                The                Development Plan and any amendments thereto adopted in accordance                with                Article 4 will form a part of this                Agreement. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.28   | “**Discontinued                Licensed Patent**”                shall have the meaning set forth in Section                8.5.3. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.29   | **“Dispute”**                shall have the meaning set forth in Section                13.1.1. |
|--------------------|-------------------------------------------------------------------------------------------------------------|

| 1.1.30   | “**Dollars**”                or “**$**”                shall mean the lawful money of the United States of                America. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.31   | “**Effective                Date**”                means the date shown on page one of this                Agreement. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------|

| 1.1.32   | “**Excess                Amount**”                shall have the meaning set forth in Section 9.2.6. |
|--------------------|------------------------------------------------------------------------------------------------------------------|

| 1.1.33   | "**Fair                Market Value**"                for the purposes of Sections 1.1.64                and 1.1.94,                means the highest price, expressed in dollars, that an asset (whether                tangible or intangible) would bring in an open and unrestricted market,                between a willing buyer and a willing seller who are both knowledgeable,                informed, and prudent, and who are acting independently of each                other. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.34   | “**FDA**”                means the Food and Drug Administration of the United States of                America. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------|

| 1.1.35   | “**FMV**”                means the quotient resulting from dividing (A) the sum of the value                of all                trades for each of the twenty (20) trading days immediately preceding                the                FMV reference date, by (B) the aggregate volume of all trades of                shares of                Common Stock during such twenty trading day period, in each case                as                reported in the principal exchange or stock market on which the Common                Stock is then listed. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.36   | **“FTE                Rate”**                means the fully burdened rate established by INEX for the services                of an                INEX employee or consultant providing IP Services which for the first                year                of this Agreement, is $[***] based on 1,800 employee hours per year,                or                pro-rata portion thereof; provided however, that on each anniversary                of                the Effective Date, the FTE Rate shall be adjusted                by                a percentage equal to the net                change                in                the Consumer Price Index (All Items) for the province of British                Columbia                for the twelve (12) month period ending with December of the calendar                year                immediately preceding such anniversary date.  |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.1.37   | “**GCP                Requirements**”                or “**Good                Clinical Practices**”                means the then current standards for clinical trials for pharmaceuticals                as required by the FDA, the TPD and the equivalent Regulatory Authority                elsewhere in the Territory~~,~~                and,                as                applicable, the policies and guidelines of the International Conference                on                Harmonization in effect for the clinical testing of pharmaceutical                materials. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.38   | “**GLP                Requirements**”                or “**Good                Laboratory Practices**”                means the current Good Laboratory Practices standards required by                the FDA,                the TPD and the equivalent Regulatory Authority elsewhere in the                Territory                in effect for the testing of pharmaceutical materials as applied                to raw                materials and finished products. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.39   | “**Hana                Field**”                means all uses of the Products. |
|--------------------|--------------------------------------------------------------------------------------------|

| 1.1.40   | “**Hana                Indemnitees**”                shall have the meaning set forth in Section                12.2. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------|

| 1.1.41   | “**Hana                Intellectual Property**”                means: |
|--------------------|-----------------------------------------------------------------------------------|

| (a)   | all                Intellectual                Property Rights, patents                and patent applications (whether complete or incomplete or whether                filed                or unfiled), including registrations, in any jurisdiction world-wide,                as                well as any patents and patent applications assigned or licensed                by Hana                during the Term of this Agreement;                and |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | All                Confidential                Information owned or controlled by Hana at any time during the Term                of                this Agreement. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.42   | “**IE                Oncology**”                means IE Oncology Company Limited, an international business company                incorporated under the laws of Barbados and having its registered                office                at Bishop’s Court Hill, St. Michael,                Barbados. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.43   | “**IND**”                means an Investigational New Drug application in accordance with                the rules                and regulations of the FDA. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.44   | “**Indemnitee**”                shall have the meaning set forth in Section                12.3. |
|--------------------|--------------------------------------------------------------------------------------------------------------|

| 1.1.45   | “**Indemnitor**”                shall have the meaning set forth in Section                12.3. |
|--------------------|--------------------------------------------------------------------------------------------------------------|

| 1.1.46   | “**INEX                Indemnitees**”                shall have the meaning set forth in Section                12.1. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------|

| 1.1.47   | **“INEX                Patents”**                means                all right, title and interest in and to the inventions described                in: |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | the                patents and patent applications existing on the Effective Date that                were                originally assigned to INEX and are listed in **Exhibit****1.1.52**                attached hereto; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | any                and all patents and patent application assigned or licensed by INEX                to                Hana after the Effective Date and during the Term of this Agreement                that                are necessary and useful in the Development or Commercialization                of the                Products, subject to the terms and limitations of                any                agreement related to such patents and applications;                and |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (c)   | any                and all counterparts of the foregoing, including all divisionals,                provisionals, non-provisionals, and continuations, and all patents                issuing                on any of the foregoing and any foreign counterparts thereof, together                with all registrations, reissues, re-examinations, supplemental protection                certificates, additions, renewals or extensions thereof and any foreign                counterparts thereof. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.48   | “**INEX                Technology**”                includes: |
|--------------------|---------------------------------------------------------------------------|

| (a)   | all                technical information and know-how relating to the technology claimed                in                the INEX Patents in the Hana Field                including without limitation all such information as is                described in certain of the laboratory notebooks enumerated in Exhibit                1.1.48                attached hereto; and |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | all                Confidential Information possessed by INEX on the Effective Date                and                pertaining to the Products in the Hana Field in data, drawings, formulae,                know-how, unpatented inventions, manufacturing information,                specifications, product design histories, technical dossiers, regulatory                records, quality system documentation, whether protectable or not                as trade                secrets or otherwise including,                without limitation, standard operating procedures, technical reports,                synthetic protocols, manufacturing protocols, animal protocols, invention                disclosures, manufacturing records, process development data, formulation                records, biological, chemical, pharmacological, toxicological assay                results, controls, clinical testing data, IND data and histology                slides. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.49**  ** | **“Intellectual                Property Rights”**                means all intellectual property rights subject to protection by                intellectual property laws in any country of the world, arising under                statutory or common law, contract, or otherwise, and whether or not                perfected, including without limitation, all (a) patents, reissues                of and                reexamined patents, and patent applications, whenever filed and wherever                issued, including without limitation, continuations,                continuations-in-part, substitutes and divisions of such applications                and                all priority rights resulting from such applications; (b) rights                associated with works of authorship including without limitation                copyrights, moral rights, copyright applications, copyright registrations,                synchronization rights, mask work rights, mask work applications,                mask                work registrations; (c) rights associated with trademarks, service                marks,                trade names, logos, trade dress, goodwill and the applications for                registration and registrations thereof; (d) rights relating to the                protection of trade secrets and confidential information; (e) rights                analogous to those set forth in this Section and any and all other                proprietary rights relating to intangible property; and (f) divisions,                continuations, renewals, reissues and extensions of the foregoing                (as and                to the extent applicable) now existing, hereafter filed, issued or                acquired. |
|------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.50   | “**IP                Committee**”                shall have the meaning set forth in Section                8.1. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------|

| 1.1.51   | **“IP                Services”**                means such services as Hana deems reasonably necessary, desirable                or                helpful to evidence, maintain, protect or enforce Hana’s rights as set                forth under the Services Agreement, and as further defined in Section                8.6.2. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.52   | “**Licensed                Patents**”                means                the INEX Patents, the BCCA Patents, and the MD Anderson Patents listed                in                **Exhibit****1.1.52**                attached hereto. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.53   | “**Litigating                Party**”                shall have the meaning set forth in Section                9.2.5. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.1.54   | “**Major                Markets**”                means the countries of the United States of America, Germany,                the United Kingdom, Italy, France,                Spain. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.55   | “**Manufacture,**”                **“Manufactured”**and**“Manufacturing”**                means all or a portion of the activities of Hana, INEX,                its Affiliates                or                their respective Third Party contractors associated with the                manufacturing, filling, sampling, testing, handling, labeling, packaging                and storage of Material and all work-in-progress. “Manufacturing” and                “Manufactured” will have comparable                meanings. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.56   | “**Marqibo**”                is INEX’s trade name for Sphingosomal                Vincristine. |
|--------------------|------------------------------------------------------------------------------------------------------------------|

| 1.1.57   | **“Material**”                means all compounds, materials, substances, components or consumables                sourced or Manufactured by INEX, Hana or any of their respective                Third                Party contractors to produce Clinical Trial Material                (including Clinical Trial Material),                and Product for commercial sale, but excluding machinery and equipment. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.58   | “**Maximum                Issuance Amount**”                shall have the meaning set forth in Section                3.4. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.59   | “**MD                Anderson**”                means the University of Texas MD Anderson Cancer                Center. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.60   | “**MD                Anderson License**”                means the Patent and Technology License Agreement made as of February                14,                2000 between the Board of Regents of the University of Texas System                on                behalf of the University of Texas MD Anderson Cancer Center and INEX,                and                amended as of August 15, 2000. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.61   | “**MD                Anderson Patents**”                means the Sarris Patents and Thomas Patents that are subject to the                rights                of MD Anderson (including annual fees and royalty                rights). |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.62   | “**Method                Transfer**”                means, in respect of the Services, the transfer by INEX and/or INEX’s                Third Party contractors to Hana, Hana’s Third Party contractors and/or                INEX’s Third Party contractors, of the methods                for the testing of Material pursuant to Method Transfer protocols                mutually                agreed between the Parties,                and shall include without limitation performance of Method Transfer                qualification.. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.63   | “**NDA**”                means a New Drug Application in accordance with the rules and regulations                of the FDA. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.64   | “**Net                Sales**”                means the aggregate United States dollar equivalent of gross revenues                invoiced by Hana and its Affiliates and Sublicensees from or on account                of                the sale of Product to Third Parties, in any given calendar year,                less                deductions actually allowed or specifically allocated to Product                and                actually incurred by Hana using US GAAP and reasonable practices                with                respect to sales of all Product, consistently applied, for the                following: |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | credits                or allowances, if any, actually granted on account of recalls, rejection                or return of Product; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | insurance,                freight                or                other transportation costs incurred in shipping Product to such Third                Parties; and |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (c)   | excise                taxes, sales taxes, value added taxes, consumption taxes, customs                and                other duties or other taxes or other governmental charges imposed                upon and                paid or allowed with respect to the production, importation, use                or sale                of Product (excluding income or franchise taxes of any                kind); |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | (collectively,                the “**Permitted                Deductions**”).                The foregoing definition is subject to the                following: |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | no                deductions shall be made for any item of cost incurred by Hana, its                Affiliates or Sublicensees in preparing, Manufacturing, shipping                or                selling Product except as permitted pursuant to Sections 1.1.64(a),                1.1.64(b)                and 1.1.64(c)                inclusive; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | Net                Sales shall not include transfer between any of Hana and any of its                Affiliates or Sublicensees for resale, but Net Sales shall include                the                subsequent final sales to Third Parties by such Affiliates or                Sublicensees; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (g)   | Fair                Market Value shall be assigned to any and all non-cash consideration                such                as but not limited to any credit, barter, benefit, advantage or concession                received by Hana or its Affiliates or Sublicensees in payment for                sale of                Product; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (h)   | as                used in this definition, a “sale” shall have occurred when Product are                billed out or invoiced; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | notwithstanding                anything herein to the contrary, the following shall not be considered                a                sale of Product under this                Agreement: |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                transfer of a Product to a Third Party without consideration to Hana                in                connection with the development or testing of a Product;                or |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | the                transfer of a Product to a Third Party without consideration in connection                with the marketing or promotion of the Product (e.g.,                samples). |
|------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.65   | “**Non-Abandoning                Party**”                shall have the meaning set forth in Section                8.5.1. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.66   | “**Non-Competition                Terms**”                means the terms and conditions contained in Article 7 of the Transaction                Agreement between the Parties dated May 6,                2006. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.67   | **“Non-litigating                Party**”                shall have the meaning set forth in Section                9.2.5. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.68   | **“Notice                of Abandonment**”                shall have the meaning set forth in Section                8.5.1. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.69   | “**Party**”                means INEX or Hana and “**Parties**”                means INEX and Hana. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------|

| 1.1.70   | “**Person**”                means and includes any individual, corporation, partnership, firm,                joint                venture, syndicate, association, trust, government body, and any                other                form of entity or organization. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.1.71   | “**Pharmacovigilance**”                means all the activities associated with maintaining an effective                drug                safety monitoring system and adverse events reporting system in compliance                with the requirements of Regulatory                Authorities. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.72   | “**Prime                Rate**”                means the prime or equivalent rate quoted by the Bank of Canada from                time                to time. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.73   | “**Product**”                means any one or more of Sphingosomal Vincristine, Sphingosomal                Vinorelbine, and Sphingosomal                Topotecan. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.74   | “**Publishing                Party**”                shall have the meaning set forth in Section                10.4.1. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.75   | **“QA”**                means Quality Assurance, being that part of each management system,                within                Hana and INEX separately, having responsibility for assuring the                quality                of Material and Manufacturing in respect of compliance with Regulatory                Requirements. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.76   | **“QC”**                means Quality Control, being that part of each management system,                within                Hana and INEX separately, having responsibility for quality control                testing of Material in respect of compliance with Regulatory                Requirements. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.77   | “**Registrational                Clinical Trial**”                means any one of a Phase III clinical trial or pivotal Phase II clinical                trial conducted in furtherance of Regulatory                Approvals. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.78   | “**Regulatory                Activity**”                and “**Regulatory                Activities**”                mean any one or more of the regulatory activities to be performed                by Hana,                its Sublicensees or their respective Representatives in pursuit of                the                Development of each Product, including writing, translation, compilation,                notification, submission, filing, defense, maintenance and renewal                of                Regulatory Approvals and payment of fees associated therewith, and                meeting                with Regulatory Authorities. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.79   | “**Regulatory                Approvals**”                means all necessary and appropriate regulatory approvals which must                be                obtained before placing each Product on the market in any country                in the                Territory in which such approval is required, including without                limitation, INDs, NDAs, and any other comparable terms as applicable                with                regard to any such approvals in any other country in the                Territory. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.80   | “**Regulatory                Authorities**”                means the FDA and any other like governmental authorities, whether                federal, provincial, state or municipal, regulating the manufacture,                importation, distribution, marketing, clinical testing and/or sale                of                therapeutic substances in the                Territory. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.81   | “**Regulatory                Requirements”**means                Applicable Laws and all rules, regulations and guidances in respect                of QC                and QA procedures and processes, manufacturing and production batch                records (including the master production record), packaging, handling,                storage, delivery and retention of raw material and finished product                samples and associated support data, and all licenses, certificates,                authorizations or requirements from Regulatory Authorities in the                Territory, including but not limited to cGMP Requirements in respect                of                the Manufacture of Material. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.82 ** ** | **“Regulatory                Submission**”                means any submission or filing made in furtherance of obtaining and                maintaining any Regulatory                Approvals. |
|------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.1.83   | “**Representatives**”                means, in respect of a Person, that Person’s Affiliates and their                respective directors, officers, employees, consultants, subcontractors,                Sublicensees, agents, representatives and other persons acting under                their                authority. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.84   | “**Sarris                Patents**”                means the Sarris patents and patent applications jointly owned by                INEX and                MD Anderson, and in respect of which INEX owes MD Anderson annual                fees and                royalty obligations                as                described in the MD Anderson License. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.85   | “**Service                Agreement**”                means the Service Agreement entered into between INEX and Hana dated                May                6, 2006, and effective as of April 3,                2006. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.86   | “**Sphingosomal                Topotecan**”                means a liposome that includes sphingomyelin and cholesterol and                contains                encapsulated topotecan, wherein the sphingomyelin comprises less                than 20%                dihydrosphingomyelin. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.87   | “**Sphingosomal                Topotecan R&D Expenses**”                shall have the meaning set forth in Section                3.3.4. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.88   | “**Sphingosomal                Vincristine**”                means a liposome that includes sphingomyelin and cholesterol and                contains                encapsulated vincristine, wherein the sphingomyelin comprises less                than                20% dihydrosphingomyelin. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.89   | “**Sphingosomal                Vincristine NDA**”                shall have the meaning set forth in Section                3.1.1. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.90**  ** | **“Sphingosomal                Vincristine R&D Expenses”**shall                have the meaning set forth in Section                3.1.4 |
|------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.91   | “**Sphingosomal                Vinorelbine**”                means a liposome that includes sphingomyelin and cholesterol and                contains                encapsulated vinorelbine, wherein the sphingomyelin comprises less                than                20% dihydrosphingomyelin. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.92   | **“Sphingosomal                Vinorelbine R&D Expenses”**shall                have the meaning set forth in Section                3.2.4. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.93   | “**Sublicensee**”                means an Affiliate or Third Party to whom Hana has granted a sublicense                of                the rights granted to Hana hereunder. Without limiting the generality                of                the foregoing, a Sublicensee shall be deemed to include any Affiliate                or                Third Party who is granted a sublicense hereunder by Hana pursuant                to the                terms of the outcome or settlement of any infringement or threatened                infringement action. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.94   | "**Sublicensing                Revenue**"                means                all transaction closing payments, milestone payments, license fees                and any                other pre-Commercialization                payments (excluding royalties, sales revenue, sales commissions and                any                monies and proceeds derived from the sale of sublicensed Product)                payable                to, collected or received by Hana or its Affiliates pursuant to each                sublicense agreement entered in respect of the Licensed Patents and                INEX                Technology granted hereunder. Except as otherwise expressly provided                below, “Sublicensing                Revenue” shall not include:  |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| a)   | loans                to Hana or its Affiliate by a Sublicensee relating to the Licensed                Patents                and INEX Technology, except to the extent that the interest charged                for                such loan is less than Fair Market Value (in which case only such                difference between the interest rate charged to Hana and the interest                rate                at Fair Market Value shall constitute Sublicensing Revenue) or to                the                extent that the principal of a loan is forgiven (in which case only                such                forgiven amount shall constitute Sublicensing Revenue);                or |
|----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| b)   | equity                investments in Hana by a Sublicensee or equity of the Sublicensee                relating                to the Licensed Patents and INEX Technology, except to the extent                that                such investments are made at greater than Fair Market Value (in which                case                only the excess premium shall constitute Sublicensing Revenue). For                the                purposes of this subsection, if the shares of either Hana or its                Sublicensee are not listed on any stock exchange, the Fair Market                Value                shall be based on the price at which shares of either Hana or its                Sublicensee, as the case may be, have been issued to investors (who                are                not industry-related strategic investors or collaborative research                partners) in the then most recent bona fide arm’s length private placement                financing completed within the preceding twelve (12) months having                gross                proceeds of at least Ten Million Dollars ($10,000,000). If no such                private                placement financing has been completed, the Parties shall appoint                a                mutually acceptable Person as an independent evaluator, and if the                Parties                cannot agree on an evaluator, the Fair Market Value shall be determined                as                provided in Article 13; |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| c)   | An                exchange of rights, assets, liabilities or other interest of any                kind,                except to the extent that the economic benefit conferred upon Hana                or its                Affiliates by reason of such exchange exceeds the Fair Market Value                of the                consideration which would have been paid by Hana or its Affiliates                for                such rights, assets, liabilities or interests, as determined by:                (i) the                mutual agreement of the Parties following the application of U.S.                GAAP, or                failing mutual agreement; (ii) the binding decision of a mutually                appointed independent Third Party banker or valuator familiar with                the                pharmaceutical industry. |
|----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.95   | **“Technical                Transfer**”                means the transfer by INEX and/or INEX’s Third Party contractors to Hana,                Hana’s Third Party contractors and/or INEX’s Third Party contractors of                those aspects of the INEX Technology necessary and useful for the                Manufacture of Material, and includes Method                Transfer. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.96   | “**Term**”                shall have the meaning set forth in Section                14.1. |
|--------------------|--------------------------------------------------------------------------------------------------------|

| 1.1.97   | “**Territory**”                means all of the countries and territories of the                world. |
|--------------------|--------------------------------------------------------------------------------------------------------------------|

| 1.1.98   | “**Third                Party(ies)**”                means any Person(s) other than INEX or Hana or any of their respective                Affiliates. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 1.1.99   | “**Thomas                Patents**”                means the Thomas patent applications owned by INEX, and in respect                of                which INEX owes MD Anderson                annual fees and royalty obligations                as                set forth in the MD Anderson License. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.100   | “**US                GAAP**”                means generally accepted accounting principles applied in the United                States of America. |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 1.1.101   | “**Valid                Claim**”                means either: |
|---------------------|---------------------------------------------------------------------------|

| (a)   | a                claim of an issued and unexpired patent which has not been held                unenforceable, unpatentable or invalid by a court or other governmental                agency of competent jurisdiction, and which has not been admitted                to be                invalid or unenforceable through reissue, disclaimer or otherwise;                or |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | a                claim in a patent application, provided that if such pending claim                has not                issued as a claim of an issued patent within seven (7) years after                the                filing date of such patent application, such pending claim shall                not be a                Valid Claim for purposes of this                Agreement. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**1.2  **
**Other      Definitions**

**Article      2**
**LICENSED      PATENTS AND LICENSED TECHNOLOGY**

**2.1        **
**License**

----

**2.2        **
**License      Grant to INEX**

|                     2.2.1        | Hana                  hereby grants to INEX a non-exclusive license under the Licensed                  Patents                  and INEX Technology to make, have made, use, import and have imported                  Products solely for non-commercial research, scholarly ublication,                  education, or other non-commercial                  purposes. |
|------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 2.2.2        | Hana hereby grants to INEX a non-exclusive license                under                the Licensed Patents and INEX Technology to carry out INEX’s activities                under the Development Plan and Services                Agreement. |
|--------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| 2.2.3        | Hana hereby grants to INEX a worldwide, royalty-free,                non-exclusive license under Hana Intellectual Property to make, have                made,                use, sell, offer to sale, import, and have imported liposomes and                liposomes having an active agent encapsulated, intercalated or entrapped                therein outside the Hana Field, with the proviso that this grant                does not                extend to: |
|-------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | any                Intellectual Property Rights licensed by Hana prior to the Effective                Date,                except to the extent that such license permits Hana to grant such                rights                to Inex; or |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | any                Hana Intellectual Property directed to the active agent                itself. |
|-----------------|---------------------------------------------------------------------------------------------------|

**2.3       **
**Compliance      with Third Party Agreements**

|   | Subject                to INEX’s performance of its obligations under this Agreement, and in                consideration for INEX’s sublicense of the BCCA Patents and MD Anderson                Patents Hana                unconditionally, absolutely and irrevocably covenants and agrees                with INEX                as primary obligor, to adopt as Hana’s own obligations every obligation of                INEX contained or set forth in the BCCA Agreements and the MD Anderson                License. |
|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**2.4       **
**Sublicensing**

**            **

| (a)   | Hana                will cause each Affiliate so sublicensed to perform the terms of                this                Agreement as if such Affiliate were Hana                hereunder; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (b)   | each                Affiliate so sublicensed shall unconditionally, absolutely and irrevocably                covenant and agree with INEX as primary obligor, to adopt as its                own                obligations every obligation of Hana contained or set forth in this                Agreement                to                the extent pertinent to scope of such sublicense; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | Hana                unconditionally guarantees the performance of each Affiliate hereunder                as                if they were signatories to this Agreement to the extent the performance                or lack of performance is a breach of this                Agreement; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | the                obligations and liabilities of each Affiliate and Hana under this                Agreement shall be joint and several and INEX shall not be obliged                to seek                recourse against an Affiliate before enforcing its rights against                Hana.                For greater certainty it is hereby confirmed that any default or                breach by                an Affiliate of any term of this Agreement will also constitute a                default                by Hana under this Agreement, and INEX shall be entitled to exercise                its                rights hereunder, in addition to any other rights and remedies to                which                INEX may be entitled; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | each                sublicense shall contain covenants by the Third Party Sublicensee                for the                benefit of INEX to observe and perform similar terms and conditions                to                those in this Agreement; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | all                sublicenses granted by Hana shall be further sublicensable or assignable                without the prior written consent of INEX;                provided, however, that Hana shall not sublicense any rights granted                herein to any Person that in whole or in part, either alone or in                partnership, in collaboration or in conjunction with any Person other                than                INEX, whether as principal, agent, employee, director, officer,                shareholder, licensor or in any capacity or manner whatsoever, whether                directly or indirectly manufactures liposomal products                without first either: (i) obtaining INEX’s written consent; or (ii)                including in such sublicense a provision requiring the sublicense                to agree                that it will not use the INEX Technology for any purpose other than                the                Products; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (g)   | in                the event that Hana becomes aware of a material breach of any such                sublicense by a Third Party Sublicensee, Hana shall promptly notify                INEX                of the particulars of same and take all                commercially                reasonable steps to enforce the terms of such                sublicense; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (h)   | within                ten (10) Business Days after execution of a sublicensing agreement,                Hana                shall provide INEX with a copy thereof (provided that Hana shall                be                permitted to redact the financial terms of such                agreement); |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | all                sublicenses shall terminate upon the termination of Hana’s rights granted                herein unless events of default are cured by Hana or its Sublicensee                within the period for the cure of default after notification by INEX                as                provided by the terms of this                Agreement; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (j)   | any                Sublicensee who wishes to grant a further sublicense shall comply                with the                terms of this Section as if the further sublicense were a sublicense                hereunder, including providing to INEX and Hana the information described                in this Section, and obtaining the consent referred to in this Section,                prior to any execution of any such                sub-sublicense; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (k)  | all              sublicenses shall include an obligation for each Sublicensee to account              for and report its sales of Product on the same basis as if such sales              were sales of Hana, and INEX shall receive compensation in the same              amounts as if the sales of Product by the Sublicensee were sales of              Hana;              and |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| (l)   | Hana                shall remain responsible to INEX for the compliance of each Sublicensee                with the financial and other obligations due under this                Agreement. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**2.5        **
**Payment      of Taxes**

**Article      3**
**LICENSE      FEES, MILESTONES AND ROYALTIES**

**3.1  **
**Sphingosomal      Vincristine.**

| (a)   | [***]                Dollars ($[***]) within                ten (10) days following the                FDA’s                acceptance for review                of                an NDA submission                by                Hana relating to Sphingosomal Vincristine (the “Sphingosomal Vincristine                NDA”), which payment shall be satisfied by Hana issuing to INEX a number                of additional shares of Common Stock determined by dividing [***]                Dollars                ($[***]) by the FMV as of the Sphingosomal Vincristine NDA filing                date;                provided however, if a Regulatory Submission equivalent to an NDA                is                accepted in any of the Designated EU States before the Sphingosomal                Vincristine NDA is accepted, then [***] ([***])                the                milestone payment due under this Section 3.1.1(a)                will be paid by Hana to INEX immediately upon the acceptance of that                equivalent filing in any of the Designated EU States, and the remaining                balance will be paid by Hana to INEX immediately upon the acceptance                of                the Sphingosomal Vincristine NDA                by                the FDA; and |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (b)   | [***]                Dollars ($[***]) within                ten (10) days following Hana’s receipt of                the approval by the FDA of the Sphingosomal Vincristine NDA, which                payment                shall be made by Hana issuing to INEX a number of additional shares                of                Common Stock determined by dividing [***] Dollars ($[***]) by the                FMV as                of the date of such approval; provided however, if a Regulatory Submission                equivalent to an NDA is approved in any of the Designated EU States                before                the Sphingosomal Vincristine NDA                is approved by the FDA, [***]                ([***])                the milestone payment due under this Section                3.1.1(b) will be paid by Hana to INEX immediately upon the approval                of                that equivalent filing in any of the Designated EU States, and the                remaining balance will be paid by Hana to INEX immediately upon the                approval of the Sphingosomal Vincristine NDA by the                FDA. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | For                the avoidance of doubt, each of the milestone payments described                in                subparagraphs (a) and (b) of this Section 3.1.1 above represent one-time                payments to INEX, and shall be due only upon the first occurrence                of the                events described in each such subparagraph. For example, the milestone                payment described in subparagraph (a) above will be due only once,                following                the FDA’s acceptance for review of the Sphingosomal Vincristine                NDA.                No additional milestone payments to INEX shall be due from Hana pursuant                to subparagraph (a) in connection with any subsequent NDA                submission by Hana relating to Sphingosomal Vincristine. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | With                respect to Net Sales of Sphingosomal Vincristine in the United States,                a                royalty equal to the sum of: (i) [***] percent ([***]%) of Net Sales                in                consideration of Licensed Patents if the Product sold is embraced                within                any Valid Claim under the Licensed Patents in the United States;                (ii)                [***] percent ([***]%) of Net Sales in consideration of, and during                any                period of Product exclusivity provided by the laws of the United                States of                America, including but not limited to marketing exclusivity in the                form of                data exclusivity, pediatric exclusivity, and orphan drug designation                exclusivity; and (iii) [***] percent ([***]%) of Net Sales in                consideration of INEX Technology; provided, however, that the total                royalty paid shall be limited to [***] percent ([***]%) of cumulative                Net                Sales up to [***]Dollars ($[***]), and limited to [***] percent ([***]%)                of cumulative Net Sales exceeding [***]Dollars ($[***]); and  |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | With                respect to Net Sales of Sphingosomal Vincristine in each country                of the                Territory other than the United States, a royalty of [***] percent                ([***]%) of Net Sales in consideration of Licensed Patents and INEX                Technology; provided, however, that the total royalty paid shall                be                limited to [***] percent ([***]%) of cumulative Net Sales up to                [***]Dollars ($[***]), and increased to [***]                percent ([***]%)                of cumulative Net Sales in                excess of [***]Dollars                ($[***]). |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (a)   | If,                during a given calendar year, there is sale of a generic Sphingosomal                Vincristine or sale of an approved equivalent to Sphingosomal Vincristine                (collectively, “**Approved                Sphingosomal Vincristine Equivalents**”)                in any country in the Territory, then, for such country, the total                amount                of royalties payable to INEX for the Net Sales of Sphingosomal Vincristine                in such country during such calendar year will be reduced to [***]                percent                ([***]%) of the royalties payable to INEX pursuant to Section 3.1.2                for                such calendar year, in such country. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Sphingosomal      Vincristine R&D Expenses**

| (a)   | [***]                Dollars ($[***]); or |
|-----------------|-------------------------------------------|

| (b)   | [***]                Dollars ($[***]) per patient treated in a Registrational Clinical                Trial; |
|-----------------|--------------------------------------------------------------------------------------------------------------|

**3.2  **
**Sphingosomal      Vinorelbine**

| (a)   | [***]                Dollars ($[***]) upon on the date the first patient is enrolled in                any                clinical trial of Sphingosomal Vinorelbine conducted pursuant to                an IND                sponsored by Hana, of which [***] Dollars ($[***]) shall be paid                by wire                transfer to INEX of immediately available funds and the remaining                [***]                Dollars ($[***]) shall be paid by Hana issuing to INEX a number of                additional shares of Common Stock determined by dividing [***] Dollars                ($[***]) by the FMV as of the date of such first patient                enrollment; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | [***]                Dollars ($[***]) upon the date the first patient is enrolled in any                Phase                II clinical trial of Sphingosomal Vinorelbine conducted pursuant                to an IND                sponsored by Hana, which payment shall be made by Hana issuing to                INEX a                number of additional shares of Common Stock determined by dividing                [***]                Dollars ($[***]) by the FMV as of the date of such first patient                enrollment; and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (c)   | [***]                Dollars ($[***]) upon the approval by the FDA of an NDA relating                to                Sphingosomal Vinorelbine, which payment shall be made by Hana issuing                to                INEX a number of additional shares of Common Stock determined by                dividing                [***] Dollars ($[***]) by the FMV as of the date of such FDA approval;                provided however, if a Regulatory Submission equivalent to an NDA                is                approved in any of the Designated EU States before an NDA relating                to                Sphingosomal Vinorelbine is approved by the FDA, [***] the milestone                due                under this Section 3.2.1(c) will be paid by Hana to INEX immediately                upon                approval of that equivalent filing and the remaining balance will                be paid                by Hana to INEX immediately upon the approval of an NDA relating                to                Sphingosomal Vinorelbine by the                FDA. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | For                the avoidance of doubt, each of the milestone payments described                in                subparagraphs (a), (b) and (c) of this Section 3.21 above represent                one-time payments to INEX, and shall be due only upon the first occurrence                of the events described in each such subparagraph. For example, the                milestone payment described in subparagraph (a) above will be due                only                once, upon the the date the first patient is enrolled in a clinical                trial                of Sphingosomal                Vinorelbine conducted pursuant to an IND sponsored by Hana. No additional                milestone payments to INEX shall be due from Hana pursuant to subparagraph                (a) in connection with any subsequent clinical trials sponsored by                Hana. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | With                respect to Net Sales of Liposomal Vinorelbine in the United States,                a                royalty equal to the sum of: (i) [***] percent ([***]%) of Net Sales                in                consideration of Licensed Patents if the Product sold is embraced                within                any Valid Claim under the Licensed Patents in the United States;                (ii)                [***] percent ([***]%) of Net Sales in consideration of, and during                any                period of Product exclusivity provided by the laws of the United                States of                America, including but not limited to marketing exclusivity in the                form of                data exclusivity, pediatric exclusivity, and orphan drug designation                exclusivity; and (iii) [***] percent ([***]%) of Net Sales in                consideration of INEX Technology; provided, however, that the total                royalty paid shall be limited to [***] percent ([***]%) of cumulative                Net                Sales up to [***]Dollars ($[***]), and limited to [***] percent ([***]%)                of cumulative Net Sales in excess of [***]Dollars ($[***]);                and  |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | With                respect to Net Sales of Sphingosomal Vinorelbine in each country                of the                Territory other than the United States, a royalty of [***] percent                ([***]%) of Net Sales in consideration of Licensed Patents and INEX                Technology; provided, however, that the total royalty paid shall                be                limited to [***] percent ([***]%) of cumulative Net Sales up to                [***]Dollars ($[***]), and increased to [***] percent ([***]%) of                cumulative Net Sales in excess of [***]Dollars                ($[***]). |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (a)   | If,                during a given calendar year, there is sale of a generic Sphingosomal                Vinorelbine or sale of an approved equivalent to Sphingosomal Vinorelbine                (collectively, “**Approved                Sphingosomal Vinorelbine Equivalents**”)                in any country in the Territory, them, for such country, the total                amount                of royalties payable to INEX for the Net Sales of Sphingosomal Vinorelbine                in such country during such calendar year will be reduced to [***]                percent                ([***]%) of the royalties payable to INEX pursuant to Section 3.2.2                for                such calendar year, in such                country. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Sphingosomal      Vinorelbine R&D Expenses**

| (a)   | [***]                Dollars ($[***]); or |
|-----------------|-------------------------------------------|

| (b)   | [***]                Dollars ($[***]) per patient treated in a Registrational Clinical                Trial; |
|-----------------|--------------------------------------------------------------------------------------------------------------|

**3.3  **
**Sphingosomal      Topotecan**

| 3.3.1   | Milestone                Payments: |
|-------------------|------------------------------------|

| (a)   | [***]                Dollars ($[***])                upon the date the first patient is enrolled in any clinical trial                of                Sphingosomal Topotecan conducted pursuant to an IND sponsored by                Hana,                which payment shall be made by Hana issuing to INEX a number of additional                shares of Common Stock determined by dividing [***] Dollars ($[***])                by                the FMV as of the date of such first patient                enrollment; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | [***]                Dollars ($[***]) upon the date the first patient is enrolled in a                Phase II                clinical trial of Sphingosomal Topotecan conducted pursuant to an                IND                sponsored by Hana, which payment shall be made by Hana issuing to                INEX a                number of additional shares of Common Stock determined by dividing                [***]                Dollars ($[***]) by the FMV as of the date of such first patient                enrollment; and |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (c)   | [***]                Dollars ($[***]) upon the approval by the FDA of an NDA relating                to                Sphingosomal Topotecan, which payment shall be made by Hana issuing                to                INEX a number of additional shares of Common Stock determined by                dividing                [***] Dollars ($[***]) by the FMV as the date of such FDA approval;                provided however, if a Regulatory Submission equivalent to an NDA                is                approved in any of the Designated EU States before an NDA relating                to                Sphingosomal Topotecan is approved by the FDA, [***] the milestone                due                under this Section 3.3.1(c) will be paid by Hana to INEX immediately                upon                approval of that equivalent filing and the remaining balance will                be paid                by Hana to INEX immediately upon the approval of an NDA relating                to                Sphingosomal Topotecan by the FDA. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | For                the avoidance of doubt, each of the milestone payments described                in                subparagraphs (a), (b) and (c) of this Section 3.3.1 above represent                one-time payments to INEX, and shall be due only upon the first occurrence                of the events described in each such subparagraph. For example, the                milestone payment described in subparagraph (a) above will be due                only                once, upon the the date the first patient is enrolled in a clinical                trial                of Sphingosomal Topotecan conducted pursuant to an IND sponsored                by Hana.                No additional milestone payments to INEX shall be due from Hana pursuant                to subparagraph (a) in connection with any subsequent clinical trials                sponsored by Hana. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | With                respect to Net Sales of Sphingosomal Topotecan in the United States,                a                royalty equal to the sum of: (i) [***]                percent ([***]%)                of Net Sales in consideration of Licensed Patents if the Product                sold is                embraced within any Valid Claim under the Licensed Patents in the                United                States; (ii) [***]                percent ([***]%)                of Net Sales in consideration of, and during any period of Product                exclusivity provided by the laws of the United States of America,                including but not limited to marketing exclusivity in the form of                data                exclusivity, pediatric exclusivity, and orphan drug designation                exclusivity; and (iii) [***]                percent ([***]%)                of Net Sales in consideration of INEX Technology; provided, however,                that                the total royalty paid shall be limited to [***]                percent ([***]%)                of cumulative Net Sales up to [***]Dollars                ($[***]),                and limited to [***]percent                ([***]%)                of cumulative Net Sales exceeding [***]Dollars                ($[***]);                and  |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | With                respect to Net Sales of Sphingosomal Topotecan in each country of                the                Territory other than the United States, a royalty of [***]                percent ([***]%)                of Net Sales in consideration of Licensed Patents and INEX Technology;                provided, however, that the total royalty paid shall be limited to                [***]                percent ([***]%)                of cumulative Net Sales up to [***]Dollars                ($[***]),                and increased to [***]                percent ([***]%)                of cumulative Net Sales in excess of [***]Dollars                ($[***]). |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (a)   | If,                during a given calendar year, there is sale of a generic Sphingosomal                Topotecan or sale of an approved equivalent to Sphingosomal Topotecan                (collectively, “**Approved                Sphingosomal Topotecan Equivalents**”)                in any country in the Territory, them, for such country, the total                amount                of royalties payable to INEX for the Net Sales of Sphingosomal Topotecan                in such country during such calendar year will be reduced to [***]                percent                ([***]%) of the royalties payable to INEX pursuant to Section 3.3.2                for                such calendar year, in such                country. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Sphingosomal      Topotecan R&D Expenses**

| (a)   | [***]                Dollars ($[***]); or |
|-----------------|-------------------------------------------|

| (b)   | [***]                Dollars ($[***]) per patient treated in a Registrational Clinical                Trial; |
|-----------------|--------------------------------------------------------------------------------------------------------------|

**3.4  **
**Limitation      on Payment **
**Using      Common Stock**

**Maximum      Issuance Amount**

**3.5  **
**Assumption      of Milestone and Royalty Obligations**

| 3.5.1   | As                a condition of the grant of licence of the Licensed Patents and INEX                Technology by INEX to Hana, Hana                shall assume all payment obligations of INEX to BCCA and to MD Anderson,                in respect of all license fees, annual fees, milestone payments,                royalty                payments and any other like payments, including all interest and                taxes                attributable thereto, arising from Hana or its Sublicensees’ use of the                Licensed Patents within the Hana Field                under the BCCA Agreements and the MD Anderson License. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 3.5.2   | For                avoidance of doubt, the obligations of Hana under Section 3.5.1 are                in                addition to and not in substitution of any other obligations set                forth in                this Article 3. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**3.6  **
**Remuneration      Respecting Sublicensees**

| 3.6.1   | In                the event Hana sublicenses its rights under Sphingosomal Vincristine                before the FDA approves the Sphingosomal Vincristine NDA or a Designated                EU State approves a Regulatory Submission that is equivalent to an                NDA,                INEX shall be entitled to receive [***]                percent ([***]%)                of any Sublicensing Revenue payable to Hana by such Sublicensee.                In the                event Hana sublicenses its rights to Sphingosomal Vincristine after                the                FDA approves the Sphingosomal Vincristine NDA or a Designated EU                State                approves a Regulatory Submission that is equivalent to an NDA, INEX                shall                be entitled to receive [***]                percent ([***]%)                of any Sublicensing Revenue payable to Hana by such                Sublicensee. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.6.2   | In                the event Hana sublicenses its rights under Sphingosomal Vinorelbine,                INEX                shall be entitled to share the Sublicensing Revenue payable to Hana,                if                any, as follows: |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | INEX’s                share of such Sublicensing Revenue shall be [***]                percent ([***]%) of any Sublicensing Revenue payable to Hana by such                Sublicensee during the period commencing on the Effective Date and                ending                on the date immediately preceding the date the first patient is enrolled                in a Phase II clinical trial of Sphingosomal                Vinorelbine; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | INEX’s                share of such Sublicensing Revenue shall be reduced to [***] percent                ([***]%) of any                Sublicensing Revenue payable to Hana by such Sublicensee on or after                the                date the first patient is enrolled in Phase II clinical trial of                Sphingosomal Vinorelbine and ending on the date immediately preceding                the                earlier to occur of: |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                date the first patient is enrolled in a Phase III clinical trial                of                Sphingosomal Vinorelbine; or |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | the                acceptance of the NDA or its equivalent Regulatory Submission for                Sphingosomal Vinorelbine; and |
|------------------|-----------------------------------------------------------------------------------------------------------------------------------|

| (c)   | INEX’s                share of such Sublicensing Revenue shall be reduced to [***]                percent ([***]%) of any Sublicensing Revenue payable to Hana by such                Sublicensee on or after the earlier to occur                of: |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                date the first patient is enrolled in a Phase III clinical trial                of                Sphingosomal Vinorelbine; or |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | the                acceptance of the NDA or its equivalent Regulatory Submission for                Sphingosomal Vinorelbine. |
|------------------|-------------------------------------------------------------------------------------------------------------------------------|

----

| 3.6.3   | In                the event Hana sublicenses its rights under Sphingosomal Topotecan,                INEX                shall be entitled to share the Sublicensing Revenue payable to Hana,                if                any, as follows: |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | INEX’s                share of such Sublicensing Revenue shall be [***]                ([***]%) of any Sublicensing Revenue payable to Hana by such Sublicensee                during the period commencing on the Effective Date and ending on                the date                immediately preceding the date the first patient is enrolled in a                Phase II                clinical trial of Sphingosomal                Topotecan; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | INEX’s                share of such Sublicensing Revenue shall be reduced to [***] percent                ([***]%) of any Sublicensing Revenue payable to Hana by such Sublicensee                on or after the date the first patient is enrolled in Phase II clinical                trial of Sphingosomal Topotecan and ending on the date immediately                preceding the earlier to occur of: |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                date the first patient is enrolled in a Phase III clinical trial                of                Sphingosomal Topotecan, or |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | the                acceptance of the NDA or its equivalent Regulatory Submission for                Sphingosomal Topotecan. |
|------------------|-----------------------------------------------------------------------------------------------------------------------------|

| 3.6.4   | Notwithstanding                anything to the contrary contained in this Section 3.6, Hana shall                have no                obligation to pay to INEX its respective share of any such Sublicensing                Revenue unless and until Hana                actually                receives such Sublicensing Revenue from its                Sublicensee. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.6.5   | Where                any Sublicensing Revenue payable to, collected or received by Hana                or its                Affiliates is in Dollars, Hana shall pay to INEX, INEX’s share of such                Sublicensing Revenue within ten (10) days of Hana or its Affiliate’s                receipt of same. Where any Sublicensing Revenue payable to, collected                or                received by Hana or its Affiliates is derived from a country other                than                the United States of America, INEX’s portion of such Sublicensing Revenue                shall be converted to the equivalent in Dollars on the same date                that Hana                converts such Sublicensing Revenue to Dollars, in which case the                amount of                Dollars pursuant to an actual conversion shall be included in the                Sublicensing Revenue and Hana shall pay to INEX, INEX’s share of such                Sublicensing Revenue within ten (10) days of such conversion. If                at any                time the Parties agree that it is not practical or possible for Hana                to                forthwith convert Sublicensing Revenue paid in foreign currency to                Dollars, or if legal restrictions prevent the conversion of part                or all of                the Sublicensing Revenue to Dollars, Hana shall have the right and                option,                upon consultation with INEX, to deposit INEX’s share of such Sublicensing                Revenue in local currency, in an account in INEX’s sole name in a bank or                depository in the country where such Sublicensing Revenue is generated.                Hana                shall make such deposit within ten (10) days of Hana or its Affiliate’s                receipt of said foreign currency. The last date of signature of any                duly                executed sublicensing agreement between Hana and a Sublicensee shall                be                deemed to be the date upon which Sublicensing Revenue is received                by Hana                for the purposes of determining the percentage of Sublicensing Revenue                payable to INEX pursuant to Sections 3.6.1, 3.6.2 and 3.6.3.                Hana shall make Commercially Reasonable Efforts to inform INEX in                a timely                manner of material legislative and economic changes in such country                in                which such deposit was made so as to enable INEX to more readily                access,                convert and/or transfer from such country, INEX’s share of Sublicensing                Revenue deposited in such country by                Hana. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 3.6.6   | Notwithstanding                Section 3.6.5,                if                any Sublicensing Revenue other than cash is payable to, collected                or                received by Hana or its Affiliates,                Hana may elect to pay to INEX, INEX’s share of Sublicensing Revenue by way                of cash, common stock of Hana, common stock of another corporation                acceptable to INEX, or any combination thereof. If Hana elects to                pay INEX                using the Common Stock of Hana or the common stock of another corporation                acceptable to INEX, the following shall                apply: |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | the                last date of signature of any duly executed sublicensing agreement                between                Hana and a Sublicensee shall be deemed to be the date upon which                Sublicensing Revenue is received by Hana for the purposes of determining                the percentage of Sublicensing Revenue payable to INEX pursuant to                Sections 3.6.1,                3.6.2                and 3.6.3; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | the                value of the economic benefit of the Sublicensing Revenue established                by a                Third                Party banker or valuator, measured in Dollars and applied to the                percentage entitlement of INEX determined pursuant to Section 3.6.6(a),                shall be the assessed value (the “**Assessed                Value**”)                to be used in determining the number of shares of Common Stock of                Hana or                common stock of                another corporation acceptable to INEX                payable to INEX pursuant to Section 3.6.6(c);                and |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | Hana                will pay INEX using Common Stock of Hana or common stock of another                corporation acceptable to INEX as                follows: |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (i)   | the                Parties will mutually agree on the par value per share of common                stock of                Hana or of another corporation acceptable to INEX;                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (ii)   | Hana                will issue or assign to INEX as applicable, a number of shares of                Common                Stock of Hana or common stock of another corporation acceptable to                INEX by                dividing the Assessed Value by the FMV as of the date upon which                Sublicensing Revenue was deemed to have been received by Hana pursuant                to                Section 3.6.6(a). |
|------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | Hana’s                payment of Sublicensing Revenue in the form of stock pursuant to                this                Section shall be made within ten (10) days of Hana’s receipt of                same. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.6.7   | Hana’s                payment of Sublicensing Revenue under this Section 3.6 shall be                accompanied by an accounting setting out all Sublicensing Revenue                payable                to, collected or received by Hana or its Affiliates, segmented according                to Product, Sublicensee identified by name, and the last date on                which                each sublicensing agreement was                executed. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**3.7  **
**Third      Party Payments**

| 3.7.1   | If,                during the Term of this Agreement:  |
|-------------------|-------------------------------------------------------------|

----

| (a)   | Hana                and INEX mutually agree that it is necessary to seek a license from                any                Third Party in the Territory in order to avoid infringement during                the                exercise of the rights herein granted; or |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | if                as a result of any complaint alleging infringement or violation of                any                patent or other Intellectual Property Rights is made against Hana,                its                Affiliate or its Sublicensee with respect to the Manufacture, use                or sale                of a Product in the Hana Field, where such Manufacture, use or sale                is                encompassed by one or more Licensed Patents or INEX Technology, and                a                settlement, consent judgement or award of Damages determined by a                court of                competent jurisdiction requires Hana to make payment of Damages to                a Third                Party in satisfaction of such complaint; or |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | if                an independent, mutually acceptable Third Party patent attorney determines                that such a license is required (in accordance with the procedure                outlined                in this Section 3.7.1); |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Offset      Amount**
**Punitive      Amount**

| 3.7.2   | Notwithstanding                the provisions of Section 3.7.1, if the license from the Third Party                or                the royalty or other amount payable to such Third Party gives rise                to an                indemnification obligation under one or more the Definitive Agreements                in                favour of Hana on the part of INEX, then such royalty or other amount                shall be paid by INEX as Damages in accordance therewith; provided,                however, that Hana agrees to use all reasonable efforts to avoid                a finding                of willful infringement of such Third Party’s                rights. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**3.8  **
**Compulsory      Licenses**

| 3.8.1   | avail                itself of the royalty reduction set out in Sections 3.1.3, 3.2.3,                or                3.3.3, if applicable; or |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.8.2   | have                the benefit in such country of the same terms granted to such Third                Party                to the extent that such terms taken as a whole are more favourable                than                those of this Agreement. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**3.9  **
**Reports      and Payment**

| 3.9.1   | all                Net Sales segmented in each such report according to sales by Hana,                each                Affiliate and each Sublicensee, as well as on a country-by-country                basis,                and month-by-month basis; |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.9.2   | deductions                from gross revenues by the categories for same set out in the definition                of Net Sales; and |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------|

| 3.9.3   | the                rates of exchange used to convert such royalties to Dollars from                the                currency in which such sales were made. For the purposes hereof,                such                conversion calculations are to be made on a monthly basis and the                rates of                exchange to be used for converting royalties hereunder to Dollars                shall be                those in effect for the purchase of Dollars as certified by the noon                buying rate of the Federal Reserve Bank of New York on the first                Business                Day of the quarter with respect to which the payment is                due. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**3.10  **
**Withholding      Taxes**

| 3.10.1   | Hana                shall be deemed to be the sole payer of payments owed to INEX under                this                Agreement and shall not have the right to substitute any domestic                or                foreign Affiliate for that purpose,                and |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.10.2   | in                the event that Hana takes any action, including, without limitation,                the                assignment of this Agreement, any sublicensing permitted hereby,                any                change of jurisdiction of residence or any reorganization or change                in its                business or structure so that, after such action, the withholding                tax on                the payments under this Agreement would be substantially more than                those                in effect on the Effective Date, Hana shall                either: |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | with                the co-operation of INEX, arrange its affairs so that the withholding                tax                consequences to INEX are not materially worse than those in effect                prior                to such action; or |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | gross                up the payments otherwise owed to INEX so that INEX receives net                of                withholding taxes the amount INEX would have received but for such                action. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**3.11  **
**Foreign      Payments**

**3.12  **
**Method      of Payment**

**3.13  **
**Late      Payments**

| 3.13.1   | the                Prime Rate(s) during the period of late payment plus [***] percent                ([***]%) interest compounded monthly,                or |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 3.13.2   | the                maximum rate permitted by law; |
|--------------------|---------------------------------------------------|

**3.14  **
**Records**

**3.15  **
**Audits**

----

**Article      4**
**DEVELOPMENT      OBLIGATIONS**

**4.1  **
**Development      Plans**

| 4.1.1   | Hana,                with INEX’s assistance, shall prepare for the Parties’ review and                discussion, a detailed Development Plan for the Development of each                Product. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.1.2   | The                Development Plan shall describe the specific Clinical Activities,                Regulatory Activities, Technical Transfer activities, and Manufacturing                activities to be performed in the Territory for the                twelve (12) month period                following the Effective Date. The                Development Plan will be reviewed from time to time as the Parties                reasonably determine to be necessary or useful. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.1.3   | The                Development Plan shall be incorporated herein by reference and all                Development undertaken thereunder shall be conducted by Hana in compliance                with Regulatory Requirements. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**4.2  **
**Development      Efforts**

| 4.2.1   | Hana                shall use Commercially Reasonable Efforts to Develop each Product                in the                Territory (including carrying out its responsibilities under the                Development Plan) to: |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | conduct                or cause to be conducted the necessary and appropriate clinical trials                as                necessary to obtain and maintain Regulatory Approvals for each Product;                and |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | prepare,                file and prosecute or cause to be prepared, filed and prosecuted                the                Regulatory Submission for each                Product. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 4.2.2   | Hana                will provide INEX with written reports to keep INEX fully informed                of the                progress of the Development of each Product as                follows: |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | at                the close of each Calendar Quarter during the first twenty-four (24)                months following the Effective Date;                and |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | on                or before June 31 and December 31 of each and every calendar year                thereafter. |
|-----------------|----------------------------------------------------------------------------------------------------------------|

**4.3  **
**Transition      Committees**

**4.4  **
**Subcontractors**

----

**Article      5**
**COMMERCIALIZATION      OBLIGATIONS**

**5.1  **
**Regulatory      Compliance**

**5.2  **
**Marqibo      **
**Trademark**

| 5.2.1   | INEX                shall cause its wholly owned Affiliate, IE Oncology, to assign to                Hana all                applications for trademark and all registered trademarks for Marqibo                in                all jurisdictions within the Territory as soon as reasonably                possible. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.2.2   | Except                as provided herein, Hana at its sole cost and expense, shall be                responsible for the selection, registration and maintenance of all                other                trademarks which it employs in connection with each Product in the                Territory and shall own and control such trademarks during the Term                of                this Agreement and following its termination or                expiration. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**5.3  **
**Labeling      and Patent Marking**

**5.4  **
**Commercialization      Efforts**

**5.5  **
**Consequence      of No Sales**

| 5.5.1   | In                addition to the terms of Section 5.4,                Hana shall be deemed to have breached its obligation to use Commercially                Reasonable Efforts in conducting marketing of a Product in any country                in                the Major Markets if, for a continuous period of one hundred and                eighty                (180) days at any time following launch of commercial sales of the                Product                in any such country in the Major Markets, no sales of the Product                are made                in the ordinary course of business in such country by Hana, an Affiliate                or a Sublicensee, unless: |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | the                Parties mutually agree it is to their mutual benefit to delay commercial                sales of Product in such country;                or |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana                is prevented, restricted, interfered with or delayed in making such                sales                by reason of a cause beyond Hana’s reasonable control and can demonstrate                same to INEX; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 5.5.2   | If                Hana breaches its obligation set forth in Section 5.5.1: |
|-------------------|----------------------------------------------------------------------------|

| (a)   | INEX                shall be entitled to terminate all rights granted to Hana in the                Definitive Agreements in respect of each such Product in such country                in                the Major Markets by written notice to Hana in the event that Hana                is in                default of its obligations under Section 5.5.1                and fails to remedy such default within sixty (60) days after notice                thereof by INEX;  |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | All                sublicenses granted by Hana in respect of each such Product in such                country in the Major Markets shall forthwith terminate upon the effective                date of termination in Section 5.5.2(a);                and |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | Hana                shall continue to be bound by and shall comply with Sections 14.6,                14.8,                and any other Sections which are intended to survive any termination                of                rights under this Agreement. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**5.6  **
**Reports**

| 5.6.1   | Hana                shall deliver to INEX within thirty (30) days after the end of each                Calendar Quarter reports setting forth in general terms, reasonably                sufficient for evaluation of the diligence obligations contained                herein,                the efforts Hana has made to Commercialize the Product during the                year,                including any significant adverse developments, and any plans for                or                occurrences of any commercial sales of the Product in any jurisdiction                and                a summary of the efforts it intends to make in the upcoming year(s)                on                these matters.                Hana shall consider any INEX input and comments related to Hana’s plan for                the upcoming year(s), provided that it is understood that Hana shall                have                final decision making responsibility for such                plans. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 5.6.2   | To                the extent that such could not be appropriately communicated to INEX                in                accordance with Section 5.6.1,                Hana shall keep INEX informed in a timely manner of significant                developments in Hana’s (and its Affiliates’ and Sublicensees’, as the case                may be) progress of its efforts to Commercialize the Product, including                without limitation, any significant adverse developments, and any                plans                for or occurrences of any commercial sales of the Product in any                jurisdiction. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      6**
**PRODUCT      SAFETY AND REGULATORY COMPLIANCE**

**6.1  **
**Regulatory      Responsibilities**

| 6.1.1   | Hana                shall use                its Commercially Reasonable Efforts to ensure                that                none of its Representatives who participate in any Development                activities: |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | is                or has been suspended, debarred or disqualified by the                FDA; |
|-----------------|----------------------------------------------------------------------------------------------|

----

| (b)   | has                been convicted of any offence that would form the basis for any                suspension, disqualification or debarment;                or |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | is                or has been subject to any proceedings for the suspension,                disqualification or debarment. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------|

| 6.1.2   | Upon                the re-activation and/or transfer by INEX to Hana of the NDA or IND,                as                the case may be, in respect of each Product, Hana shall be responsible                for                using                Commercially Reasonable Efforts to maintain and fulfill                all Regulatory Requirements with respect to such Product that                are                imposed upon Hana as the holder of Regulatory Submissions and Regulatory                Approvals. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.1.3   | Hana                and/or its Representatives’ Manufacturing, shipping and distribution of                Material for clinical and commercial use shall be done in accordance                with                applicable specifications and Regulatory Requirements. Hana shall                maintain                and shall require its Representatives who receive, handle, store,                ship or                distribute Product to maintain a record retention policy consistent                with                cGMP and Regulatory Requirements, and to maintain records with sufficient                detail to facilitate traceability in the event of recalls or voluntary                withdrawals of Product. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.1.4   | In                respect of each Product, Hana will use Commercially                Reasonable Efforts                to                make such changes as reasonably necessary to the master production                record,                specifications,                procedures, processes, Materials, facilities, equipment or any matter                utilized by Hana under this Agreement or contained or reference in                and                documents submitted to Regulatory Authorities to meet new Regulatory                Requirements and guidelines in the                Territory. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**6.2  **
**Pharmacovigilance**

| 6.2.1   | Upon                the transfer                by                INEX to Hana of the INDs for Sphingosomal Vinorelbine and Sphingosomal                Topotecan, and the NDA for Sphingosomal Vincristine, Hana shall be                responsible for, in respect of each such Product, performing                Pharmacovigilance in respect of all pre-Regulatory Approval Clinical                Activities and all post-Regulatory Approval Product safety monitoring                in                accordance with Regulatory Requirements, in addition to all other                Regulatory Activities for which Hana is                responsible. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.2.2   | For                as long as Material sourced, Manufactured or quantity released by                INEX                remains available for use in approved clinical trials, Hana                shall: |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | inform                INEX within five (5) Business Days of any complaint received or regulatory                action taken in respect of such Material and shall seek INEX’ opinion                before passing judgment on the quality of such Material to any Third                Party; and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | provide                INEX with a copy(ies) of all documentation provided to and received                from                Regulatory Authorities in respect of such complaint or Adverse Drug                Event,                within one (1) Business Day of sending or receiving                same. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**6.3  **
**Recalls      and Product Withdrawals**

| 6.3.1   | If                either Party is required or requested by any Regulatory Authority                to                recall or withdraw any Clinical Trial Material for any reason, or                should                either Party decide voluntarily to withdraw any Clinical Trial                Material: |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | the                Party in whose name the applicable IND file is registered will be                responsible for coordinating such recall or product                withdrawal; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana                shall pay the costs and expenses of such recall or product withdrawal,                subject to recovery of some or all of same in accordance with the                terms of                Section 6.3.2; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | Unless                INEX is liable for such costs and expenses in accordance with the                terms of                Section 6.3.2, Hana will remain responsible to INEX for payment of                all                services in respect of the Manufacture and supply of Material;                and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | Both                Parties will cooperate fully with one another in connection with                any such                recall or product withdrawal. |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.3.2   | If                a recall or product withdrawal is due to INEX’s negligence, willful                misconduct or breach of this Agreement or of the Service Agreement,                INEX                will reimburse Hana for all of Hana’s reasonable costs and expenses                actually incurred by Hana in connection with the recall or product                withdrawal, including any Service fees and expenses associated with                the                supply of the Product recalled or withdrawn, costs of retrieving                Product                already delivered to customers, costs and expenses Hana is required                to pay                for notification, shipping and handling charges, destruction or return                of                the defective Product or otherwise and such other reasonable costs                as may                be reasonably related to the recall or product                withdrawal. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.3.3   | If                the Parties are unable to agree on whether or not a recall or product                withdrawal is due to INEX’s negligence, willful misconduct or breach of                this Agreement, either Party may refer the matter for resolution                pursuant                to Article 13. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 6.3.4   | Notwithstanding                any expiration or early termination of this Agreement, the provisions                of                Sections 6.2 and 6.3 shall continue to apply for as long as any Product                containing Material that was sourced, Manufactured or quality released                by                INEX remains available for use in approved clinical                trials. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      7**
**INTELLECTUAL      PROPERTY RIGHTS**

**7.1  **
**Injunctive      Relief**

----

**7.2  **
**INEX      Title**

| 7.2.1   | the                license granted to Hana under this                Agreement; |
|-------------------|---------------------------------------------------------------------------------|

| 7.2.2   | the                rights of the BCCA (including royalty obligations) under the BCCA                Agreements, in respect of the BCCA Patents;                and |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.2.3   | the                rights of MD Anderson (including royalty obligations) under the MD                Anderson License in respect of the MD Anderson                Patents. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**7.3  **
**Ownership      of Pre-existing Intellectual Property Rights**

**7.4  **
**Ownership      of Future Intellectual Property Rights**

| 7.4.1   | Subject                to the Non-Competition Terms and to any Notice of Abandonment that                INEX                may issue in respect of any Intellectual Property Rights related                to the                Products, all right, title and interest in and to any and all Intellectual                Property Rights that arise after the Effective Date and are related                to the                Products shall be owned                as follows:  |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | MD                Anderson and INEX shall be the joint owners of any patents and patent                applications filed after the Effective Date that claim priority to                the                Sarris Patents; |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | INEX                shall be the exclusive owner of any patents and patent applications                filed                after the Effective Date that claim priority to the Thomas Patents;                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | INEX                shall be the exclusive owner of any patents and patent applications                filed                after the Effective Date that claim priority to the INEX                Patents;  |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | All                Intellectual Property Rights of INEX existing before the Effective                Date of                this Agreement and all Intellectual Property Rights developed solely                by                employees or agents of INEX or an Affiliate after the Effective Date                shall                be and will remain the exclusive property of INEX, and subject to                the                license grant of Section 2.1; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | Subject                to Sections 2.2, 7.4.1(a),                7.4.1(b)                and 7.4.1(c),                all Intellectual Property Rights conceived and reduced to practice                solely                by employees or agents of Hana or an Affiliate relating to the Products                shall be and remain the exclusive property of Hana and subject to                the                license grant of Section 2.2; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (g)   | Subject                to Sections 7.4.1(a),                7.4.1(b)                and 7.4.1(c),                any Intellectual Property Rights developed jointly by one or more                employees or agents of each of INEX and Hana or their Affiliates                relating                to the Products shall be owned exclusively by Hana, and subject to                the                license grant of Section 2.2;                and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (h)   | Each                Party shall ensure that its Representatives who perform any portion                of its                obligations under this Agreement have entered into written agreements                with                such Party whereby such Representatives assign to such Party all                ownership                rights in any Intellectual Property Rights made or developed by such                Representatives in the course of such work for such                Party. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.4.2   | Each                Party further agrees to execute, acknowledge and deliver to the requesting                Party such other instruments of conveyance and transfer and will                take such                other actions and execute, acknowledge and deliver such other documents,                certifications and further assurances as the requesting Party may                reasonably require in order to: (i) vest more effectively in the                requesting Party any rights transferred hereby, including but not                limited                to, obtaining registration or regulatory approval of any assets acquired                or rights granted hereunder or derivative works thereof; or (ii)                better                enable the requesting Party to exercise the rights acquired by such                Party                hereunder. Each of the Parties hereto will cooperate with the other                and                execute and deliver to the other Party such other instruments and                documents and take such other actions as may be reasonably requested                from                time to time by any other Party as necessary to carry out, evidence                and                confirm the intended purposes of this Agreement.  |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 7.4.3   | Hana                agrees that in negotiating any joint venture, collaborative research,                development, Commercialization or other agreement(s) it may have                with any                Person other than INEX under which any Intellectual Property Rights                related to the Products may arise after the Effective Date, Hana                shall                include in such agreements, provisions that provide for the assignment                or                license, as the case may be, of such Intellectual Property Rights                by such                Person(s) and their representatives to INEX in accordance with                Article                (a),                (b)                and (c). |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      8**
**PATENT      PROSECUTION AND MAINTENANCE**

**8.1  **
**IP      Committee**

**IP      Committee**

**8.2  **
**Responsibility      for Patent Prosecution and Maintenance**

| 8.2.1   | In                respect of all patents and patent applications that are listed in                **Exhibit****1.1.52**,                Hana shall be responsible for: |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | the                continued prosecution of any such pending patent applications to                the issuance of the resulting                patents; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | the                maintenance of all such issued Licensed Patents;                and |
|-----------------|----------------------------------------------------------------------------------------|

----

| (c)   | the                filing of additional patent applications for such Licensed Patents                in any                jurisdiction world-wide, including, without limitation, any continuations,                continuations-in-part, divisionals, patents of addition, reissues,                re-examinations and extensions of or substitutes therefore, which                additional patent applications (and resulting patents) shall be                automatically included in the Licensed Patents, and the provision                of this                Article 8 shall apply thereto. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **(d)**   | All                reasonable costs and expenses arising from Hana’s patent prosecution and                maintenance shall be allocated between the Parties pro-rata based                on the                percentages set forth in **Exhibit****1.1.52**. |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2.2   | Notwithstanding                the allocation of patent prosecution and maintenance costs set forth                in                this Section 8.2, if Hana requests IP Services from INEX in respect                of any                activities which would otherwise have been performed by Hana pursuant                to                Section 8.2.1, INEX shall be entitled to payment of IP Services in                accordance with the provisions of Section 8.6 and the Service                Agreement. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2.3   | Hana                shall be responsible for the prosecution of the pending patent                applications included in the Licensed Patents in accordance with                the                responsibilities set forth in Section 8.2.1 and cost allocations                set forth                in **Exhibit****1.1.52**.                The cost allocations set out in **Exhibit****1.1.52**** **shall                be subject to review and amendment by mutual agreement of the Parties                on                an annual basis on or before December 31 of each year during the                Term. In                the event that the parties cannot reach agreement on or before December                31, the matter will be resolved by arbitration in accordance with                Article                13. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2.4   | Hana                shall diligently pursue the prosecution of all patent applications                in                accordance with the responsibilities set forth in Section 8.2.1 and                cost                allocations set forth in **Exhibit****1.1.52**** **to                issuance of the resulting patents and shall not abandon, withdraw                or                discontinue prosecution of any pending patent applications included                in the                Licensed Patents without first consulting with and obtaining the                prior                written consent of INEX, which consent shall not be withheld if the                Parties agree that the issuance of a patent from such application                is                unlikely. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2.5   | At                the request of INEX, Hana shall diligently pursue and prosecute additional                patent filings relating to the Licensed Patents and INEX Technology                in any                jurisdiction worldwide in accordance with the responsibilities set                forth                in Section 8.2.1 and cost allocations set forth in **Exhibit****1.1.52**. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.2.6   | Either                Party may request the other Party to file new patent applications,                divisionals, provisionals, non-provisionals, continuations and                continuations-in-part to ensure that Valid Claims on Licensed Patents                remain pending. If the Party having primary responsibility for patent                prosecution and maintenance decides not to meet such request, the                requesting Party shall be entitled to, at the requesting Party’s                election: |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | refer                the matter to arbitration pursuant to Article                13;                or |
|-----------------|---------------------------------------------------------------------------------------------------------|

| (b)   | perform                such filings and take such actions as it deems necessary and at its                sole                cost. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------|

----

| (c)   | cooperate                with the requesting Party perform such filings and take such actions                as                may be required by the requesting Party if the requesting Party does                not                have standing to perform such filings and take such actions;                or |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | grant                the requesting Party a power-of-attorney to perform such filings                and take                such actions as may be required by the requesting                Party; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**8.3  **
**Consultation**
**      and Reporting**

| 8.3.1   | On                a timely basis, Hana will consult with or instruct its patent agent(s)                and/or patent counsel(s) to consult with INEX, and INEX will consult                with                or instruct its patent agent(s) and/or patent counsel(s) to consult                with                Hana, regarding the claims and any proposed amendments thereto                of: |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | any                Licensed Patents pending and issued;                and |
|-----------------|----------------------------------------------------------------------------|

| (b)   | any                additional patent applications to be included in the Licensed                Patents; |
|-----------------|----------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| (c)   | to ensure that the scope of patent coverage is adequate              for the uses of the Licensed Patents contemplated by each of Hana and              INEX. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.3.2   | On                a timely basis, Hana shall provide INEX with copies of the material                correspondence and documents which Hana sends or receives in connection                with the application, prosecution and maintenance of Licensed                Patents. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.3.3   | Provided                a Party has provided timely notice and copies of material correspondence                to the other Party of any matter requiring any action relating to                any                application, prosecution or maintenance of the Licensed Patents,                the Party                providing timely notice shall not be found to be in breach of its                obligations under this Article 8 if the other Party, its patent agent(s)                and/or patent counsel(s) fail to consult with or provide written                instructions to the Party providing timely notice, at least five                (5)                Business Days prior to any deadline including an extendible deadline,                in                respect of any action required for the application, prosecution or                maintenance of the Licensed                Patents. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**8.4  **
**Reports**

**8.5  **
**Abandonment,      Withdrawal or Discontinuance**

| 8.5.1   | Notwithstanding                each Party’s obligation under Section 8.2, should either Party decide                to: |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------|

| (a)   | discontinue                pursuing one or more patent applications, patent protection or patent                maintenance for one or more patents in relation to the Licensed Patents                or                any continuation, continuation-in-part, divisional, reissue,                re-examination or extension thereof for any                reason; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (b)   | not                pursue patent protection in relation to the Licensed Patents in any                specific jurisdiction for any reason;                or |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | discontinue                or not pursue patent protection in relation to any further process,                use or                Product arising out of the Licensed Patents in any jurisdiction for                any                reason; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Abandoning      Party**
**Non-Abandoning      Party**
**Notice      of Abandonment**

| 8.5.2   | The                Notice of Abandonment to be given by the Abandoning Party pursuant                to                Section 8.5.1 shall clearly identify the patent applications, patent                protection, and/or patent maintenance for the Licensed Patents to                be                abandoned. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.5.3   | Each                of the Parties agrees that notwithstanding any provision to the contrary                in this Agreement, effective upon the date of the Non-Abandoning                Party’s                receipt of the Notice of Abandonment, the Abandoning Party shall                lose all                rights under: |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | the                patent(s) and patent application(s) to which such Party’s Notice of                Abandonment applies; and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | any                continuation, continuation-in-part, divisional, reissue, re-examination,                or extension of or to the                foregoing; |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------|

|  |                  (c) | (any                  one of the above being the “**Discontinued                  Licensed Patent**”). |
|--|---------------------------|--------------------------------------------------------------------------------------------------------------------|

| 8.5.4   | If                Hana gives Notice of Abandonment to INEX pursuant to Sections 8.5.1                and                8.5.2, this license shall be terminated with respect solely to the                Discontinued Licensed Patent, and Hana shall forfeit the right to                any and                all uses of the Discontinued Licensed Patent and INEX Technology                claimed                in such Discontinued Licensed Patent. **Exhibits                1.1.47**and                **1.1.43**will                be deemed to be amended to exclude such Discontinued Licensed Patent                and                INEX Technology claimed in such Discontinued Licensed Patent from                the                grant of license contained herein. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.5.5   | If                Hana has given Notice of Abandonment to INEX pursuant to Sections                8.5.1                and 8.5.2, and INEX wishes to continue to pursue any patent applications,                patent protection and/or patent maintenance in relation to Hana’s                Discontinued Licensed Patent: |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | within                ten (10) Business Days of INEX’s receipt of Hana’s Notice of Abandonment,                INEX shall provide Hana with written notice of INEX’s intention to pursue                any patent applications, patent protection and/or patent maintenance                in                relation to Hana’s Discontinued Licensed                Patent; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | Hana                shall relinquish patent prosecution and maintenance of Hana’s Discontinued                Licensed Patent and INEX shall assume patent prosecution and maintenance                of same, at INEX’s sole cost and expense;                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (c)   | notwithstanding                the Non-Competition Terms, INEX shall have the exclusive right to                use                Hana’s Discontinued Licensed Patent and inventions claimed in Hana’s                Discontinued Licensed Patent, in the Hana                Field. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.5.6   | If                INEX gives Notice of Abandonment to Hana pursuant to Sections 8.5.1                and                8.5.2, INEX shall forfeit the right to any and all uses of the                Discontinued Licensed Patent and inventions claimed in any Discontinued                Licensed Patent, notwithstanding that INEX may remain the nominal                owner of                such Discontinued Licensed Patent. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.5.7   | If                INEX has given Notice of Abandonment to Hana pursuant to Sections                8.5.1                and 8.5.2 and Hana wishes to continue to pursue any patent applications,                patent protection and/or patent maintenance in relation to INEX’s                Discontinued Licensed Patent: |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | within                ten (10) Business Days of Hana’s receipt of INEX’s Notice of Abandonment,                Hana shall provide INEX with written notice of Hana’s intention to pursue                any patent applications, patent protection and/or patent maintenance                in                relation to INEX’s Discontinued Licensed Patent, at Hana’s sole cost and                expense; and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | notwithstanding                the Non-Competition Terms, Hana shall have the exclusive right to                use                INEX’s Discontinued Licensed Patent and the inventions claimed in INEX’s                Discontinued Licensed Patent, outside the Hana                Field. |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.5.8   | Either                Party may request the other Party to perform such other Party’s                responsibilities set forth in Sections 8.2.1 or 8.2.2, as the case                may be,                in respect of a particular patent or patent application. If the Party                bearing such responsibility is unwilling or unable to perform its                responsibility in a timely manner, the Party requesting performance                in                respect of such patent or patent application may, with three (3)                days                prior written notice, perform the particular activity(ies) requested                in                respect of such patent or patent application. The Party unwilling                or                unable to perform its responsibility shall pay all reasonable costs                and                out-of-pocket expenses actually incurred by the requesting Party                to                perform the particular activity(ies) requested, within thirty (30)                days of                the non-performing Party’s receipt of the performing Party’s invoice for                such costs and out-of-pocket expenses. For the purposes of this Section                8.5.8, reasonable costs shall                be calculated using the FTE Rate set forth in the Service Agreement,                regardless of the Party performing the activity(ies), and notwithstanding                any termination of the Service                Agreement. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**8.6  **
**Costs      of Patent Application, Prosecution and Maintenance**

| 8.6.1   | Commencing                from the date that an Abandoning Party has lost all entitlement to                a                discontinued Licensed Patent, such Abandoning Party shall not be                required                to share in any costs (and services fees if INEX is the Abandoning                Party)                associated with the application, prosecution, and/or maintenance                of any                Licensed Patents in the Discontinued License                Patent. |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.6.2   | Subject                to Section 8.6.1, and notwithstanding any termination of the Service                Agreement, for as long as INEX continues to perform at Hana’s request, the                activities required for intellectual property portfolio management                and all                associated activities including, without limitation, patent application,                filing, prosecution and maintenance, and payment of all government                and                legal fees required to apply for, prosecute and maintain the Licensed                Patents described in Section 8.2.1 (the “**IP                Services**”),                Hana, its successors, assigns or any Person(s) who acquires any interest                in any of the Licensed Patents and INEX Technology will jointly and                severally be responsible for paying                INEX: |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (a)   | [***]percent                ([***]%)                of all reasonable out-of-pocket costs, including, without limitation,                filing fees, fees for external counsel(s), patent agent(s), contractors,                travel, and lodging expenses incurred by INEX to provide IP Services;                and |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | [***]percent                ([***]%)                of the personnel costs incurred by INEX, calculated at INEX’s FTE Rate,                pro rated to reflect the actual time employees, contractors or consultants                of INEX spend providing IP Services; provided however, that on each                anniversary of the Effective Date, the FTE Rate shall be raised by                a                percentage equal to the percentage increase in the Consumer Price                Index                (All Items) for the province of British Columbia for the twelve (12)                month                period ending with December of the calendar year immediately preceding                such anniversary date; and |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | [***]percent                ([***]%)                of all out-of-pocket costs and [***]percent                ([***]%)                of all personnel costs incurred by INEX to provide IP Services in                respect                of any Discontinued Licensed Patent which Hana has elected to continue                pursuing patent protection, pursuant to Section                8.5.5. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.6.3   | INEX                will invoice Hana monthly for all costs set forth in Section 8.6.2,                plus                all applicable taxes thereon, on or before the 30th                day after the end of the month in which the IP Services were rendered                and/or expenses incurred; provided however, that any out-of-pocket                costs                incurred which are not captured in any invoice may be captured in                subsequent invoices. Hana will pay all amounts due and payable hereunder                in full in Dollars to INEX within thirty (30) days of the date of                each                such invoice, by cheque or wire transfer to the account specified                by                INEX. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.6.4   | Notwithstanding                Section 8.6.3, during the Term, INEX shall not combine Hana’s payment                obligations for IP Services under the Service Agreement together                with                Hana’s payment obligations under this Section 8.6 to recover from Hana,                its successors, assigns or any Person(s) who acquires any interest                in any                of the Licensed Patents and INEX Technology, more than the total                monthly                costs set forth in Section 8.6.2 in any given                month. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**8.7  **
**Late      Payments**

| 8.7.1   | the                Prime Rate(s) during the period of late payment plus [***] percent                ([***]%) interest compounded monthly;                or |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.7.2   | the                maximum rate permitted by law; |
|-------------------|---------------------------------------------------|

----

**8.8  **
**Co-operation**

| 8.8.1   | making                available to the other Party or such other Party’s Representatives whom                the other Party in its reasonable judgment deems necessary in order                to                assist it in obtaining patent protection of the Licensed Patents;                and |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 8.8.2   | executing                and causing its Representatives to execute all legal documents reasonably                necessary to support the assignment, filing, prosecution and maintenance                of said Licensed Patents. |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      9**
**INFRINGEMENT      PROCEEDINGS**

**9.1  **
**Limits**

| 9.1.1   | an                obligation by Hana or INEX to bring or prosecute or defend actions                or                suits against Third Parties for infringement of patents, copyrights,                trademarks, industrial designs or other intellectual property or                contractual rights; or |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.1.2   | the                conferring by Hana or INEX of the right to use in advertising or                publicity                the name of Hana or INEX or their respective                trademarks. |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**9.2  **
**Conduct      of Infringement Proceedings**

| 9.2.1   | an                alleged infringement by a Third Party of the Licensed Patents or                INEX                Technology or of any right with respect to the Licensed Patents or                INEX                Technology by the manufacture,                sale, services or use of products derived from the Licensed Patents                or                INEX Technology in the Hana Field; or |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2.2   | any                complaint by Hana alleging any infringement by a Third Party with                respect                to the Licensed Patents or INEX Technology or to any right with respect                to                the Licensed Patents or INEX Technology by the manufacture,                sale, services or use of products derived from the Licensed Patents                or                INEX Technology in the Hana Field; |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2.3   | Hana shall                have the first right, in its sole discretion, and at its sole expense,                to                prosecute or defend such                litigation; |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2.4   | if                Hana                does not take steps to prosecute or defend such litigation within                thirty                (30) days after receipt of notice thereof, INEX                may take such legally permissible action as it deems necessary or                appropriate to prosecute such litigation or defend such                litigation at its own expense, but shall not be obligated to do                so; |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 9.2.5   | the                Party prosecuting or defending such litigation (in this Article,                the                “**Litigating                Party**”)                shall have the right to control such litigation and shall bear all                legal                expenses (including court costs and legal fees), including settlement                thereof provided however that no settlement or consent judgment or                other                voluntary final disposition of any suit defended or action brought                by a                Party pursuant to this Section 9.2 may be entered into without the                consent                of the other Party if such settlement would require the other Party                to be                subject to an injunction or to make a monetary payment or would restrict                the claims in or admit any invalidity of any Licensed Patents or                significantly adversely affect the rights of the other Party to this                Agreement (the “**Non-litigating                Party**”).                By way of example and not by way of limitation, there shall be no                right of                the Litigating Party to stipulate or admit to the invalidity or                unenforceability of any Licensed Patents. Before any action is taken                by                the Litigating Party which could abridge the rights of the Non-litigating                Party hereunder, the Parties agree to, in good faith, consult with                a goal                of adopting a mutually satisfactory                position; |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2.6   | the                Non-litigating Party agrees to co-operate reasonably in any such                litigation to the extent of executing all necessary documents, supplying                essential documentary evidence and making essential witnesses then                in its                employment available and to vest in the Litigating Party the right                to                institute any such suits, so long as all the direct or indirect costs                and                expenses of bringing and conducting any such litigation or settlement                shall be borne by the Litigating Party, provided that INEX and Hana                shall                recover their respective actual out-of-pocket expenses, or equitable                proportions thereof, associated with any litigation or settlement                thereof                from any recovery made by any Party. Any excess amount remaining                after                satisfaction of the Parties’ recovery of their respective actual                out-of-pocket expenses, or equitable proportions thereof, associated                with                any litigation or settlement thereof from any recovery made by any                Party                (the “**Excess                Amount**”)                shall be shared between                Hana and INEX on                the same basis as set forth in Sections 3.1, 3.2 and 3.3 with respect                to                Royalties from Net Sales of Product in the applicable                jurisdiction;                provided however, that any Excess Amount in the form of punitive                Damages                shall be shared between Hana and INEX in proportion to each Party’s                contribution to litigation expenses. In the event a settlement or                consent                judgement does not distinguish between the forms of Damages payable                by the                Third Party, and Hana and INEX cannot agree on what portion, if any,                of                the Excess Amount constitutes punitive Damages, the Parties will                refer the                matter to arbitration in accordance with Article                13. |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2.7   | the                Litigating Party shall keep the Non-litigating Party fully informed                of the                actions and positions taken or proposed to be taken by the Litigating                Party (on behalf of itself or a sublicensee) and actions and positions                taken by all other parties to such litigation;                and |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.2.8   | in                the event that INEX prosecutes or defends such litigation, Hana may                elect                to participate formally in the litigation to the extent that the                court may                permit, but any additional expenses generated by such formal participation                shall be paid by Hana (subject to the possibility of recovery of                some or                all of such additional expenses as                described in Section 9.2.6 or from                such other parties to the                litigation). |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**9.3  **
**Breach      of Confidence Proceedings**

----

**9.4  **
**Defense      of Infringement Proceedings**

| 9.4.1   | If                any complaint alleging infringement or violation of any patent or                other                proprietary rights is made against Hana, its Affiliate or Sublicensee                with                respect to the Manufacture, use or sale of a Product, the following                shall                apply: |
|-------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | Hana                shall promptly notify INEX in writing upon receipt of any such complaint                setting out full details thereof and shall keep INEX fully informed                of the                actions and positions taken by the complainant and taken or proposed                to be                taken by Hana (on behalf of itself, or a                Sublicensee); |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | if                such complaint gives rise to an indemnification obligation under                any of                the Definitive Agreements in favor of Hana (or its Affiliate or                Sublicensee) on the part of INEX, then INEX shall defend such suit                and                all                costs and expenses incurred by Hana (or any Affiliate                or Sublicensee)                in investigating, resisting, litigating and settling such a complaint,                including the payment of any award of Damages and/or costs to any                Third                Party, shall be paid by INEX; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | if                such complaint does not give rise to an indemnification obligation                under                the Definitive Agreements in favor of Hana on the part of INEX, then                Hana                shall have the right but not the obligation to defend such suit and                all                costs and expenses incurred by Hana (or any Affiliate                or Sublicensee)                in investigating, resisting, litigating and settling such a complaint,                including the payment of any award of Damages and/or costs to any                Third                Party, shall be paid by Hana (or any Affiliate                or Sublicensee,                as the case may be); and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | in                any event, INEX and Hana shall assist one another and cooperate in                any                such litigation at each Party’s own                expense. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.4.2   | If                any complaint alleging infringement or violation of any patent or                other                proprietary rights is made against INEX, its Affiliate or sublicensee                with                respect to the Manufacture, use or sale of a Product, the following                procedure shall apply: |
|-------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | INEX                shall promptly notify Hana in writing                upon receipt of any such complaint setting out full details thereof                and                shall keep Hana fully informed of the actions and positions taken                by the                complainant and taken or proposed to be taken by                INEX; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | if                such a complaint gives rise to an indemnification obligation under                the                Definitive Agreements in favor of INEX on the part of Hana, then                Hana                shall defend such suit and all costs and expenses incurred by INEX                (or its                Affiliate) in investigating, resisting, litigating and settling such                a                complaint, including the payment of any award of Damages and/or costs                to                any Third Party, shall be paid by                Hana. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | If                such complaint does not give rise to an indemnification obligation                under                the Definitive Agreements in favor of INEX on the part of Hana, then                INEX                shall have the right but not the obligation to defend such suit and                all                costs and expenses incurred by INEX (or its Affiliate) in investigating,                resisting, litigating and setline such a complaint, including the                payment                of any award of Damages and/or costs to any Third Party, shall be                paid by                INEX; |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (d)   | In                any event, INEX and Hana shall assist one another and cooperate in                any                such litigation at each Party’s own                expense. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.4.3   | With                regard to costs and expenses incurred by Hana (or any Sublicensee)                under                Sections 9.4.1(c)                or                9.4.2(b)                in                investigating, resisting, litigating and settling such a complaint,                including the payment of any award of Damages and/or costs to any                Third                Party (the “**Offset                Amount**”),                but not including any punitive award (the “**Punitive                Amount**”),                Hana (or any Sublicensee) shall be entitled to offset or credit [***]                percent ([***]%) of the Offset Amount against future payments otherwise                due INEX as set forth in Section 3.7.1.                With regard to any Punitive Amount (eg. willful infringement), the                same is                not included in the Offset Amount and is not to be offset or credited                against future payments due INEX. |
|-------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.4.4   | In                the event a complaint is made under either of Sections 9.4.1                or                9.4.2,                no settlement or consent judgment or other voluntary final disposition                may                be entered into without the consent of the other Party if such settlement                would require the other Party to be subject to an injunction or to                make a                monetary payment or would restrict the claims in or admit any invalidity                of any Licensed Patents or significantly adversely affect the rights                of                the other Party. |
|-------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**9.5  **
**Co-operation      with Other Licensees**

| 9.5.1   | fields                outside of the Hana Field that may reasonably affect Hana’s use of the                Licensed Patents or INEX Technology in the Hana Field or the Manufacture,                use or sale of Product by Hana; or |
|-------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 9.5.2   | the                Hana Field that may reasonably affect INEX or one or more of INEX’s                sublicensees use of the Licensed Patents or INEX Technology outside                the                Hana Field or the manufacture, use or sale of products outside the                Hana                Field by INEX or one or more other such                sublicensee(s); |
|-------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      10**
**CONFIDENTIAL      INFORMATION AND PUBLICATION**

**10.1  **
**Treatment      of Confidential Information**

| 10.1.1   | to                keep and use in strict confidence all Confidential Information of                the                other Party that each Party acquires, sees, or is informed of, as                a direct                or indirect consequence of this Agreement and to not, without the                prior                written consent of the other Party, disclose any such Confidential                Information or recollections thereof to any Person other than its                Representatives who are under an obligation of confidentiality on                terms                substantially similar to those set out in this Agreement, who have                been                informed of the confidential nature of the Confidential Information                and                who require such information in connection with the performance of                this                Agreement; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 10.1.2   | that                all copies, duplicates, reproductions, translations or adaptations                of any                Confidential Information of the other Party made hereunder shall                be                clearly labeled as confidential;                and |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.1.3   | to                take all reasonable steps to prevent material in its possession that                contains or refers to Confidential Information of the other Party                from                being discovered, used or copied by Third Parties and that it shall                use                reasonable steps to protect and safeguard all Confidential Information                of                the other Party in its possession from all loss, theft or                destruction. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**10.2  **
**Permitted      Disclosures**

| 10.2.1   | where                in the reasonable and unqualified opinion of the receiving Party’s legal                counsel, disclosure is required to be made                under: |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | the                securities laws of any relevant jurisdiction, including the receiving                Party’s jurisdiction of incorporation or a jurisdiction in which the                receiving Party’s securities are traded on a stock exchange;                or |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | such                disclosure is required to be made by the receiving Party or its                Representatives under the terms of a valid and effective subpoena                or order                issued by a court of competent jurisdiction or by an administrative                body                or government authority; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | the                receiving Party shall immediately notify the disclosing Party prior                to any                such disclosure and the disclosing Party shall have been given the                opportunity where possible to oppose such disclosure by the receiving                Party by seeking a protective order or other appropriate remedy,                or to                waive compliance with the provisions of this                Agreement; |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | the                receiving Party or its Representatives, as the case may be, shall                disclose                only that portion of the information legally required to be disclosed,                and |
|-----------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (e)   | the                receiving Party or its Representatives, as the case may be, will                exercise                all reasonable efforts to maintain the confidential treatment of                the                information; and |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.2.2   | to                Third Party contractors or collaborators to facilitate or carry out                the                Parties’ performance of their respective                activities under this Agreement,                provided that such Third Parties enter into an agreement                with such Party which contains confidentiality provisions substantially                the same as those set forth herein. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**10.3  **
**Liability      for Representatives**

**10.4  **
**Publications**
**      Generally**

| 10.4.1   | at                least thirty (30) days before any proposed submission is submitted                and any                proposed publication is published by a Party (the “**Publishing                Party**”)                ,                such                Publishing Party shall provide the other Party with an advance copy                of any                such proposed submission or proposed publication, as the case may                be,                before any other disclosure of same and such other Party shall have                a                reasonable opportunity to recommend any changes it reasonably believes                are                necessary to preserve Intellectual Property Rights or Confidential                Information belonging in whole or in part to INEX or Hana, and the                incorporation of such recommended changes shall not be unreasonably                refused; and |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 10.4.2   | if                such other Party informs the Publishing Party, within thirty (30)                days                after receipt of an advance copy of a proposed publication, that                such                publication in its reasonable judgment could be expected to have                a                material adverse effect on any Intellectual Property Rights or                Confidential Information belonging in whole or in part to INEX or                Hana,                the Publishing Party shall delay or prevent such publication as proposed.                In the case of inventions, the delay shall be sufficiently long to                permit                the timely preparation and filing of a patent application(s) or                application(s) for a certificate of invention on the information                involved                but not more than ninety (90) days. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**10.5  **
**No      Limitation on Regulatory Compliance**

**10.6  **
**Return      of Confidential Information**

----

**Article      11**
**REPRESENTATIONS      AND WARRANTIES**

**11.1  **
**Hana      Representations and Warranties**

| 11.1.1   | Hana                is a corporation duly organised, existing, and in good standing under                the                laws of Delaware and has the power, authority, and capacity to enter                into                this Agreement and to carry out the transactions contemplated by                this                Agreement, all of which have been duly and validly authorised by                all                requisite corporate proceedings; |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.2   | the                execution, delivery and performance by Hana of this Agreement do                not                contravene or constitute a default under any provision of applicable                law                or its articles or by-laws (or equivalent documents) or of any judgment,                injunction, order, decree or other instrument binding upon                Hana; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.3   | all                licenses, consents, authorizations and approvals, if any, required                for the                execution, delivery and performance by Hana of this Agreement have                been                obtained and are in full force and effect and all conditions thereof                have                been complied with, and no other action by or with respect to, or                filing                with, any governmental authority or any other Person is required                in                connection with the execution, delivery and performance by Hana of                this                Agreement; |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.4   | this                Agreement constitutes a valid and binding agreement of Hana, enforceable                against Hana in accordance with its terms, except as such enforceability                may be limited by bankruptcy, insolvency, moratorium or creditors’ rights                generally; |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.5   | the                execution, delivery and performance by Hana of this Agreement do                not and                will not conflict with or result in a material breach of any of the                terms                and provisions of any Third Party agreement of Hana entered into                as of the                Effective Date; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.6   | Hana                is not aware of any impediment, including without limitation any                Third                Party agreement of Hana, which would prevent Hana from performing                its                obligations under this Agreement; |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.7   | Hana                will not enter into any Third Party agreement after the Effective                Date                which, in any way, will prevent                Hana from performing                all of its                obligations hereunder; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.8   | The                authorized capital stock                of                Hana consists                of 100,000,000 shares of Common Stock, of which 22,658,202 shares                are                issued and outstanding as of the date of this Agreement, and 10,000,000                shares of preferred stock, par value $0.001 per share, none of which                is                issued and outstanding. All of such issued and outstanding shares                of                Common Stock                have been                validly issued and are outstanding as fully paid and                non-assessable; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.9   | the                issuance of the Common Stock has been duly authorized by all necessary                action on the part of Hana and no further action is required by Hana                or                its board of directors or shareholders to complete the issuance of                the                Common Stock; |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.1.10   | the                Common Stock, when issued, will be duly and validly issued, fully                paid and                non-assessable and will be free and clear of all liens, charges,                encumbrances and any rights of others. Hana has reserved from its                duly                authorized capital stock a number of shares sufficient to meet its                obligations to issue the Common Stock hereunder;                and |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 11.1.11   | no                consent, approval, authorization or other order of any governmental                authority is required to be obtained by Hana in connection with the                authorization and issuance of Common Stock, except for such registrations,                filings or notices as have been made or as may be required to be                made                pursuant to U.S. or Canadian securities                laws. |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**11.2  **
**INEX      Representations and Warranties**

| 11.2.1   | INEX                is a corporation duly organised, existing, and in good standing under                the                laws of British Columbia and has the power, authority, and capacity                to                enter into this Agreement and to carry out the transactions contemplated                by this Agreement, all of which have been duly and validly authorised                by                all requisite corporate                proceedings; |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.2   | the                execution, delivery and performance by INEX of this Agreement do                not                contravene or constitute a default under any provision of applicable                law                or its articles or by-laws (or equivalent documents) or of any judgment,                injunction, order, decree or other instrument binding upon                INEX; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.3   | all                licenses, consents, authorizations and approvals, if any, required                for the                execution, delivery and performance by INEX                of                this Agreement have been obtained and are in full force and effect                and all                conditions thereof have been complied with, and no other action by                or with                respect to, or filing with, any governmental authority or any other                Person                is required in connection with the execution, delivery and performance                by                INEX                of                this                Agreement |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.4   | this                Agreement constitutes a valid and binding agreement of INEX, enforceable                against INEX in accordance with its terms, except as such enforceability                may be limited by bankruptcy, insolvency, moratorium or creditors’ rights                generally |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.5   | the                execution, delivery and performance by INEX of this Agreement do                not and                will not conflict with or result in a material breach of any of the                terms                and provisions of any Third Party agreement of INEX entered into                as of the                Effective Date; |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.6   | INEX                is not aware of any impediment, including without limitation any                Third                Party agreement of INEX, which would prevent INEX from performing                its                obligations under this Agreement;                and |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.7   | INEX                will not enter into any Third Party agreement after the Effective                Date                which, in any way, will prevent                INEX from performing                all of its                obligations                hereunder. |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.8   | to                the best of the knowledge of INEX, INEX holds the entire right title                and                interest in and to the Licensed Patents and INEX Technology, free                and                clear of all encumbrances and INEX has the right and power to grant,                on an                exclusive basis, the licences granted to Hana under this Agreement                without                consent of any Third Party that may claim any such interest through                INEX,                including, without limitation, any secured creditor of                INEX. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 11.2.9   | to                the best of the knowledge of INEX, all the Licensed Patents are validly                subsisting and all maintenance fees and similar annuity payments                have been                made in each of the jurisdictions requiring such                payments; |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.10   | to                the best of the knowledge of INEX, all statements contained in any                applications for the registration of the Licensed Patents were true                and                correct as of the date of such applications;                and |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.11   | except                for the Intellectual Property Rights described in this Agreement,                INEX                neither owns nor controls any Intellectual Property Rights that would                be                required by Hana in order to make, have made, use, sell, offer for                sale,                import, and have                imported Products in the Hana Field within the Territory. |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 11.2.12   | to                the actual knowledge of INEX, without independent investigation or                inquiry, the rights to the Licensed Patents and INEX Technology granted                by                INEX to Hana pursuant to this Agreement are all of the Intellectual                Property Rights necessary for Hana to make, have made, use, sell,                offer                for sale, import, and have imported Products in the Hana Field within                the                Territory, without any infringement of or conflict with the Intellectual                Property Rights of Third Parties. |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**11.3  **
**DISCLAIMER**

**Article      12**
**INDEMNIFICATION      AND LIABILITY LIMITATIONS**

**12.1  **
**Indemnification      by Hana**

**INEX      Indemnitees**

| 12.1.1   | the                breach of any representation or warranty made by Hana                herein; |
|--------------------|-------------------------------------------------------------------------------------------------|

| 12.1.2   | the                default by Hana in the performance or observance of any of its obligations                to be performed or observed                hereunder; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.1.3   | the                breach by Hana of any Regulatory Requirements, regulations and guidelines                in connection with any Product; |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------|

| 12.1.4   | any                complaint alleging infringement or violation of any patent or other                proprietary rights is made against INEX or its Affiliates with respect                to                Hana’s Manufacture, use or sale of a Product;                and |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 12.1.5   | any                injury or death to any Person or damage to any property caused by                any                Product provided by Hana or a Sublicensee, whether claimed by reason                of                breach of warranty, negligence, product defect or otherwise, and                regardless of the form in which any such claim is                made. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.1.6   | the                breach of any representation or warranty made by INEX                herein; |
|--------------------|-------------------------------------------------------------------------------------------------|

| 12.1.7   | the                default by INEX in the performance or observance of any of its obligations                to be performed or observed hereunder;                and |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.1.8   | the                breach by INEX of any Regulatory Requirements, regulations and guidelines                in connection with any Licensed Patent and INEX                Technology. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**12.2  **
**Indemnification      by **
**INEX**

**Hana      Indemnitees**

| 12.2.1   | the                breach of any representation or warranty made by INEX                herein; |
|--------------------|-------------------------------------------------------------------------------------------------|

| 12.2.2   | the                default by INEX in the performance or observance of any of its obligations                to be performed or observed hereunder;                and |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.2.3   | the                breach by INEX of any Regulatory Requirements, regulations and guidelines                in connection with any Licensed Patent and INEX                Technology; |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.2.4   | the                breach of any representation or warranty made by Hana                herein; |
|--------------------|-------------------------------------------------------------------------------------------------|

| 12.2.5   | the                default by Hana in the performance or observance of any of its obligations                to be performed or observed                hereunder; |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.2.6   | the                breach by Hana of any Regulatory Requirements, regulations and guidelines                in connection with any Product; and |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.2.7   | any                injury or death to any person or damage to any property caused by                any                Product provided by Hana or its Sublicensees, whether claimed by                reason of                breach of warranty, negligence, product defect or otherwise, and                regardless of the form in which any such claim is                made. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**12.3  **
**Notice      of Claims**

**Indemnitee**
**Indemnitor**

----

| 12.3.1   | the                Indemnitor is granted, subject to the provisions of this Section                12.3 and                the relevant provisions of Article 9, full authority and control                over the                defense, including settlement, against such claim or law suit or                other                action, and |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.3.2   | the                Indemnitee cooperates fully with the Indemnitor and its agents in                defense                of the claims or law suit or other                action. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**12.4  **
**Consequential      Losses**

**12.5  **
**Actions      Between the Parties**

**12.6  **
**Insurance**

| 12.6.1   | Prior                to or immediately upon the start of any human clinical trials or                other                product testing involving human subjects by Hana or its Sublicensee                (**“Human                Clinical Trials”**)                and for a period of five (5) years after the expiration of this Agreement                or the earlier termination thereof, Hana shall obtain and/or maintain,                respectively, at its sole cost and expense, public liability and                product                liability insurance in not                less than the following amounts, with a reputable and financially                secure                insurance carrier: |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | Each                Occurrence:     $5,000,000                Dollars |
|-----------------|-------------------------------------------------------------------------------------------|

| (b)   | General                Aggregate:  $5,000,000                Dollars |
|-----------------|---------------------------------------------------------------------------|

----

| 12.6.2   | At                all times during the Term of this Agreement and for a period of five                (5)                years after the expiration of this Agreement or the earlier termination                thereof, INEX shall obtain and/or maintain, respectively, at its                sole cost                and expense, comprehensive or commercial form general liability coverage,                including contractual liability, and public liability insurance in                not                less than the following amounts, with a reputable and financially                secure                insurance carrier:  |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | Each                Occurrence:    $4,000,000                (Canadian dollars)  |
|-----------------|------------------------------------------------------------------------------------------------------|

| (b)   | General                Aggregate: $4,000,000                (Canadian dollars) |
|-----------------|--------------------------------------------------------------------------------|

| 12.6.3   | Each                Party                shall require that such                Party’s Representatives and Hana’s                Sublicensee under this Agreement shall                either: |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | demonstrate                to the                other Party’s                reasonable satisfaction that such                Representative or                Hana’s                Sublicensee has a program of self insurance no less adequate than                that                which a reasonable and prudent businessperson carrying on a similar                line                of business would require; or |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | sixty                (60) days prior to the earlier of the start of Human Clinical Trials                or                the first sale of any such Product by Hana’s Sublicensee, procure and                maintain public liability, and product liability insurance in reasonable                amounts, with a reputable and financially secure insurance                carrier. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 12.6.4   | Notwithstanding                anything to the contrary contained in this Section 12.6,                before                the first date of commercial sale of any Product in the U.S., Hana                and its                Affiliate and Sublicensee of each such Product will maintain in full                force                and effect, with reputable insurers or pursuant to a self-insurance                program, product liability insurance to a minimum value of Five Million                Dollars ($5,000,000) per each occurrence and in the                aggregate. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      13**
**DISPUTE      RESOLUTION**

**13.1  **
**Negotiation      and Arbitration**

| 13.1.1   | Prior                to engaging in any formal dispute resolution with respect to any                dispute,                controversy or claim arising out of or in relation to this Agreement                or                the breach, termination or invalidity of this Agreement (each, a                “**Dispute**”),                the Chief Executive Officers of the Parties shall attempt to resolve                the                Dispute for a period not less than thirty (30)                days. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 13.1.2   | Except                for any Dispute with respect to Intellectual Property Rights, which                may,                at the option of the other Party, be dealt with by commencing an                action in                a court of competent jurisdiction, any Dispute that cannot be settled                amicably by agreement of the                Parties pursuant to Section 13.1.1 may, on mutual agreement of the                Parties, be finally                settled by a single arbitrator.                appointed pursuant to the rules                of The Center for Public Resource’s Institute for Dispute                Resolution. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.1.3   | The                place of arbitration shall be Seattle,                Washington                and the language to be used in the arbitration proceedings shall                be                English. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.1.4   | The                award rendered in any arbitration shall be final and binding upon                both                Parties. The judgment rendered by the arbitrator(s) shall include                costs of                arbitration, reasonable legal fees and reasonable costs for any expert                and                other witnesses. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.1.5   | Nothing                in this Agreement shall be deemed as preventing either Party from                seeking                specific performance, injunctive relief (or any other equitable relief),                in respect of any actual or threatened breach of this Agreement,                without                proof of actual damages, from any court having jurisdiction over                the                Parties and the subject matter of the Dispute as necessary to protect                either Party’s name, Confidential Information or Intellectual Property                Rights. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.1.6   | Notwithstanding                the provisions of Subsections 13.1.2 through 13.1.5 inclusive, either                Party shall be free to submit any Dispute relating to Intellectual                Property Rights                to                any court having jurisdiction over the Parties and the subject matter                of                the Dispute and to seek                such relief and remedies as are available in that                court. |
|--------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 13.1.7   | Each                Party is required to continue to perform its obligations under this                Agreement pending final resolution of any                Dispute. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      14**
**TERM      & TERMINATION**

**14.1  **
**Term**

| 14.1.1   | expiration                of the last to expire of the Licensed Patents containing Valid Claims                covering such Product in such country in the                Territory; |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.1.2   | expiration                of the last to expire period of product exclusivity covering such                Product                that is provided by the laws of such country in the Territory;                and |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.1.3   | in                respect of INEX Technology, on the date that all INEX Technology                cease to                be Confidential Information under the circumstances set out in Section                1.1.19. |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Term**

----

**14.2  **
**Termination      for Invalidity Challenge**

| 14.2.1   | Hana                will, not less than sixty (60) days prior to making any such assertion,                provide to INEX a complete written disclosure of each and every basis                then                known to Hana or its Affiliate for such assertion and, with such                disclosure, will provide INEX with a copy of any document or publication                upon which Hana or its Affiliate intends to rely in support of such                assertion; and |
|--------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.2.2   | INEX                shall be entitled, upon not less then thirty (30) days prior written                notice to Hana, to terminate the license granted to Hana under                Article                2                of                this Agreement for such Product(s) covered by the patent under challenge                in the applicable jurisdiction; provided however, that INEX shall                not                terminate such license if within thirty (30) days of Hana’s receipt of                INEX’s notification hereunder, Hana                has: |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | confirmed                by written notice to INEX that Hana no longer intends to challenge                the                validity or enforceability or any Licensed Patent;                or |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | provided                to INEX, documentation to confirm Hana’s withdrawal of its filing,                submission, or other process commenced in any court or other governmental                agency of competent jurisdcation to challenge the validity or                enforceability or any Licensed Patent. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**14.3  **
**Termination      on Bankruptcy**

| 14.3.1   | This                Agreement may be terminated by INEX by providing written notice to                Hana                upon: |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------|

| (a)   | the                bankruptcy, liquidation or dissolution of                Hana; |
|-----------------|-----------------------------------------------------------------------------------|

| (b)   | the                filing of any voluntary petition for bankruptcy, dissolution, liquidation                or winding-up of the affairs of Hana;                or |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | the                filing of any involuntary petition for bankruptcy, dissolution,                liquidation or winding-up of the affairs of Hana which is not dismissed                within one hundred twenty (120) days after the date on which it is                filed                or commenced. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.3.2   | This                Agreement may be terminated by Hana by providing written notice to                INEX                upon: |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------|

| (a)   | the                bankruptcy, liquidation or dissolution of                INEX; |
|-----------------|-----------------------------------------------------------------------------------|

| (b)   | the                filing of any voluntary petition for bankruptcy, dissolution, liquidation                or winding-up of the affairs of INEX;                or |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | the                filing of any involuntary petition for bankruptcy, dissolution,                liquidation or winding-up of the affairs of INEX which is not dismissed                within one hundred twenty (120) days after the date on which it is                filed                or commenced. Notwithstanding the bankruptcy of INEX, or the impairment                of                performance by INEX of its obligations under this Agreement as a                result of                bankruptcy of INEX, to the extent that INEX retains the rights necessary                to grant the licenses granted in this Agreement, Hana shall be entitled                to                retain the licenses granted herein, subject to INEX’s rights to terminate                this Agreement as provided in this                Agreement. |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| 14.3.3   | In                the event INEX shall: (1) make an assignment for the benefit of creditors,                or petition or apply to any tribunal for the appointment of a custodian,                receiver, or trustee for all or a substantial part of its assets;                (2)                commence any proceeding under any bankruptcy, dissolution, or liquidation                law or statute of any jurisdiction whether now or hereafter in effect;                (3)                have had any such petition or application filed or any such proceeding                commenced against it in which an order for relief is entered or an                adjudication or appointment is made, and which remains undismissed                for a                period of one hundred twenty (120) calendar days or more; (4) take                any                corporate action indicating its consent to, approval of, or acquiescence                in any such petition, application, proceeding, or order for relief                or the                appointment of a custodian, receiver, or trustee for all or substantial                part of its assets; or (5) permit any such custodianship, receivership,                or                trusteeship to continue undischarged for a period of one hundred                twenty                (120) calendar days or more (each, a “**Bankruptcy                Action**”),                and the occurance of any of the foregoing causes the applicable Party                or                any third party, including, without limitation, a trustee in bankruptcy,                to be empowered under state or federal law to reject this Agreement                or any                Agreement supplementary hereto, then Hana shall have the following                rights:  |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | In                the event of a rejection of this Agreement or any Agreement supplementary                hereto , Hana shall be permitted to receive and use any INEX Technology                and Confidential Information for the purpose of enabling it to mitigate                damages caused to Hana because of the rejection of this Agreement; |
|-----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | In                the event of a rejection of this Agreement or any agreement supplementary                hereto, Hana may elect to retain its rights under this Agreement                or any                agreement supplementary hereto as provided in Section 365(n) of the                United                States Bankruptcy Code or comparable provision of the laws of any                other                country in the Territory. Upon Hana’s written request to INEX or the                bankruptcy trustee or receiver, INEX or such bankruptcy trustee or                receiver shall not interfere with the rights of Hana as provided                in this                Agreement or in any agreement supplementary                hereto. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | In                the event of a rejection of this Agreement or any agreement supplementary                hereto, Hana may elect to retain its rights under this Agreement                or any                agreement supplementary hereto as provided in Section 365(n) of the                United                States Bankruptcy Code or comparable provision of the laws of any                other                country in the Territory without prejudice to any of its rights of                setoff                and/or recoupment with respect to this Agreement under the Bankruptcy                Code                or applicable non-bankruptcy law;                or |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (d)   | In                the event of a rejection of this Agreement or any agreement supplementary                hereto, Hana may retain its rights under this Agreement or any agreement                supplementary hereto as provided in Section 365(n) of the United                States                Bankruptcy Code or comparable provision of the laws of any other                country                in the Territory without prejudice to any of its rights under Section                503(b) of the Bankruptcy Code or comparable provision of the laws                of any                other country in the Territory. |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| (e)   | INEX                will provide Hana with thirty (30) days prior written notice of INEX’s                regulatory filings in respect of any reorganization or arrangement                proposed by INEX; |
|-----------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (f)   | any                reorganization or arrangement involving INEX, its affiliates and/or                its                wholly owned subsidiaries which does not prejudice the rights of                Hana                shall not constitute a                Bankruptcy Action for                the purposes of this Section 14.3.3                and shall not give rise to the remedies set forth in this Section                14.3.3;                and |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (g)   | if                Hana asserts any rights under Sections 14.3.3(a),                14.3.3(b),                14.3.3(c)                or 14.3.3(d),                Hana shall continue to be bound by all liabilities and obligations                imposed                upon Hana, its Affiliates and Sublicensees under this Agreement,                and                INEX’s custodian, receiver or trustee in bankruptcy shall be entitled                to                exercise against Hana, its Affiliates and Sublicensees, any remedies                available to INEX under this                Agreement. |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**14.4  **
**Termination**
**      for Material Breach**

| 14.4.1   | Except                as otherwise provided in this Agreement, either Party shall be entitled                to                terminate this Agreement by written notice to the other Party in                the event                that the other Party is in material breach of its obligations hereunder                and fails to remedy any such breach within ninety (90) days after                notice                thereof by the Party alleging breach. Any such notice                shall: |
|--------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (a)   | specifically                state that the Party not in default intends to terminate this Agreement                in                the event that the other Party fails to remedy the breach;                and |
|-----------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|   |   |
|--------|--------|
| (b)   | expressly              set forth the actions required of the other Party to remedy the              breach. |
|-----------------|-------------------------------------------------------------------------------------------------------------|

| (c)   | If                  such breach is not corrected, the Party not in breach shall have                  the right                  to terminate the license hereunder in respect of such Product or                  such                  country as to which a breach remains unremedied by giving written                  notice                  to the other Party, provided the notice of termination is given                  within six                  (6) months of one Party’s discovery of the other Party’s breach and prior                  to correction of the breach. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.4.2   | Either                Party shall be entitled to terminate the licenses granted to the                other                Party hereunder by written notice to such other Party in the event                that                such other Party is in material breach of the Non-Competition Terms,                and                fails to remedy any such breach within ninety (90) days after notice                thereof. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.4.3   | If                a Dispute arises as to whether either Party is in material breach                of its                obligations hereunder, or as to whether such Party has cured any                such                breach, either Party may invoke the dispute resolution procedure                described                in Article 13 to resolve such                Dispute. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**14.5  **
**No      Limitation on Remedies**

**14.6  **
**Consequences      of Termination**

| 14.6.1   | Upon                any termination by INEX of the license granted                hereunder: |
|--------------------|----------------------------------------------------------------------------------------------|

| (a)   | Hana                shall not be relieved of any obligations incurred prior to such                termination; |
|-----------------|-----------------------------------------------------------------------------------------------------------------|

| (b)   | each                Party shall promptly return to the other Party all written Confidential                Information, and all copies thereof (except for one archival copy                to be                retained solely for the purpose of confirming which information to                hold in                confidence hereunder); and |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (c)   | all                licenses and sublicenses granted hereunder shall forthwith                terminate. |
|-----------------|---------------------------------------------------------------------------------------------------------|

| 14.6.2   | The                termination of the license granted hereunder will be without prejudice                to: |
|--------------------|--------------------------------------------------------------------------------------------------------------|

| (a)   | INEX’s                right to receive all payments accrued from Hana pursuant to Section                8.6 as                of the effective date of such termination including, without limitation,                payment for all out-of-pocket costs and personnel costs which INEX                has                properly and reasonably incurred in providing IP Services and in                following                instructions received from Hana up to the date of such termination.                For                greater certainty, such costs shall include INEX’                reasonable and necessary non-cancelable obligations to                Third Parties actually incurred by INEX in the performance of its                obligations under this Agreement                prior to the date of notice of termination, but arising after the                date                of                notice of termination; and |
|-----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| (b)   | any                other legal, equitable or administrative remedies as to which either                Party                may then or thereafter become                entitled. |
|-----------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**14.7  **
**Disposition      of Product**

**14.8  **
**Delivery      of Data and Materials and License**

----

| 14.8.1   | Provided                that INEX shall be responsible for any reasonable associated out-of-pocket                costs associated with the following activities, Hana shall deliver                to INEX                a copy of all data (including animal and human) and such other                information, Materials, materials (including biological materials)                and                documents in Hana’s possession or control arising from the Development of                such Product that INEX may reasonably require in order to obtain                and/or                maintain Regulatory Approvals for such Product in the applicable                country(ies). INEX may, directly or through a licensee, exploit such                data,                other information, Materials, materials (including biological materials)                and documents to develop, make, have made, import, use, offer for                sale and                sell such Product in such                country(ies). |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.8.2   | Hana                shall also, within thirty (30) days after the effective date of such                termination, use all reasonable endeavors to take all steps and execute                all documents reasonably necessary to assign and/or transfer or permit                reference to (to the extent legally permissible in the relevant country)                all Regulatory Submissions and Regulatory Approvals arising from                the                Development of such Product under this Agreement in Hana's name or                in the                name of Hana's Representatives to INEX or its designee, provided                that INEX                shall be responsible for any reasonable associated out-of-pocket                costs of                transfer. |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.8.3   | In                the event that no such assignment and/or transfer and/or reference                pursuant to Section 14.8.2                may legally be made, then Hana shall forthwith surrender to INEX                or its                designee such Regulatory Submissions and Regulatory Approvals for                cancellation. |
|--------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 14.8.4   | Upon                INEX’s request, Hana shall within thirty (30) days after the effective                date of such termination, deliver to INEX or its designee any and                all                documents relating to applications, correspondences with Regulatory                Authorities, Regulatory Submissions, Regulatory Approvals, and                post-Regulatory Approval Pharmacovigilance in its possession or control                arising from the Development of such Product that are reasonably                required                for Commercialization of Product in such country(ies), provided that                INEX                shall be responsible for any reasonable associated out-of-pocket                costs of                transfer. |
|--------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**Article      15**
**GENERAL      PROVISIONS**

**15.1  **
**Amendments**

**15.2  **
**Assignment**

----

**15.3  **
**Counterparts;      Facsimile**

**15.4  **
**Entire      Agreement**

**15.5  **
**Enurement**

**15.6  **
**Exhibits**

**15.7  **
**Force      Majeure**

**15.8  **
**Further      Assurances**

**15.9  **
**Governing      Law**

**15.10  **
**Headings**

----

**15.11  **
**Independent      Legal Advice**

**15.12  **
**International      Sale of Goods Act**

**15.13  **
**Jurisdiction**

**15.14  **
**Non-Use      of Names**

**15.15  **
**Notices**

| If                to Hana:Hana                BioSciences, Inc.400                Oyster Point Boulevard, Suite 215,South                San Francisco, CA 94080U.S.A Attention:                President and/or C.E.O. Tel: Fax:                                                                              |   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------|
| If                to INEX:Inex                Pharmaceuticals Corporation#200                - 8900 Glenlyon ParkwayBurnaby,                B.C.Canada                V5J 5J8Attention:                 President                and/or C.E.O..Tel: (604)                419-3200Fax: (604)                419-3201 |   |

----

**15.16  **
**No      Implied Rights**

**15.17  **
**No      **
**Solicitation      or Hiring of Employees**

**15.18  **
**No      Third-Party Rights**

**15.19  **
**No      Waiver**

**15.20  **
**Publicity**

| 15.20.1   | neither                Party, nor any of its Affiliates, shall originate any publicity,                news                release or other public announcement, written or oral, relating to                this                Agreement or the existence of an arrangement between the Parties,                without                the prior written approval of the other Party and agreement upon                the                nature and text of such announcement or disclosure, which approval                shall                not be unreasonably withheld or delayed;                and |
|---------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 15.20.2   | the                Party desiring to make any such public announcement or other disclosure                shall inform the other Party of the proposed announcement or disclosure                in                reasonably sufficient time prior to public release, and shall provide                the                other Party with a written copy thereof, in order to allow such other                Party to comment upon such announcement or                disclosure. |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**15.21  **
**Relationship      of Parties**

----

**15.22  **
**Rights      and Remedies**

**15.23  **
**Severability**

| 15.23.1   | such                provision shall be severable from the remainder of the Agreement                in the                jurisdiction in which such provision was found to be invalid, illegal                or                unenforceable; |
|---------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 15.23.2   | the                validity, legality and enforceability of such provision will not                in any                way be affected or impaired thereby in any other jurisdiction and                the                validity, legality and enforceability of the remaining provisions                contained herein will not in any way be affected or impaired thereby,                unless in either case as a result of such determination this Agreement                would fail in its essential purpose;                and |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| 15.23.3   | the                Parties will use their best efforts to substitute for any provision                that                is invalid, illegal or unenforceable in any jurisdiction a valid,                legal                and enforceable provision which achieves to the greatest extent possible                the economic, legal and commercial objectives of such invalid, illegal                or                unenforceable provision and of this                Agreement. |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**15.24  **
**Survival**

**15.25  **
**Wording**

----

| **HANA****BIOSCIENCES,                INC.**by                its authorized signatory:                                   | **INEX                PHARMACEUTICALS****CORPORATION**by                its authorized signatory:                              |
|---------------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                      |                                                                                                                           |
|                   /s/ Mark J. AhnMark                J. AhnPresident                and Chief Executive Officer |                   /s/ Timothy RuaneTimothy                Ruane President                and Chief Executive Officer |

----